<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Fundam Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Fundam Clin Pharmacol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1472-8206</journal-id><journal-id journal-id-type="publisher-id">FCP</journal-id><journal-title-group><journal-title>Fundamental &#x00026; Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0767-3981</issn><issn pub-type="epub">1472-8206</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30776136</article-id><article-id pub-id-type="pmc">6850363</article-id><article-id pub-id-type="doi">10.1111/fcp.12454</article-id><article-id pub-id-type="publisher-id">FCP12454</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Real&#x02010;world insights into risk of developing cardiovascular disease following Gn<styled-content style="fixed-case" toggle="no">RH</styled-content> agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases</article-title><alt-title alt-title-type="left-running-head">G. George <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="fcp12454-cr-0001" contrib-type="author" corresp="yes"><name><surname>George</surname><given-names>Gincy</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0605-5507</contrib-id><xref ref-type="aff" rid="fcp12454-aff-0001">
<sup>1</sup>
</xref><address><email>gincy.e.george@kcl.ac.uk</email></address></contrib><contrib id="fcp12454-cr-0002" contrib-type="author"><name><surname>Scailteux</surname><given-names>Lucie&#x02010;Marie</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7047-9107</contrib-id><xref ref-type="aff" rid="fcp12454-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="fcp12454-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="fcp12454-cr-0003" contrib-type="author"><name><surname>Garmo</surname><given-names>Hans</given-names></name><xref ref-type="aff" rid="fcp12454-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="fcp12454-cr-0004" contrib-type="author"><name><surname>Balusson</surname><given-names>Fr&#x000e9;d&#x000e9;ric</given-names></name><xref ref-type="aff" rid="fcp12454-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="fcp12454-cr-0005" contrib-type="author"><name><surname>Cardwell</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="fcp12454-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="fcp12454-cr-0006" contrib-type="author"><name><surname>Coster</surname><given-names>Greet De</given-names></name><xref ref-type="aff" rid="fcp12454-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="fcp12454-cr-0007" contrib-type="author"><name><surname>Schutter</surname><given-names>Harlinde De</given-names></name><xref ref-type="aff" rid="fcp12454-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="fcp12454-cr-0008" contrib-type="author"><name><surname>Kuiper</surname><given-names>Josephina G.</given-names></name><xref ref-type="aff" rid="fcp12454-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="fcp12454-cr-0009" contrib-type="author"><name><surname>McMenamin</surname><given-names>&#x000da;na</given-names></name><xref ref-type="aff" rid="fcp12454-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="fcp12454-cr-0010" contrib-type="author"><name><surname>Verbeeck</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="fcp12454-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="fcp12454-cr-0011" contrib-type="author"><name><surname>Van Hemelrijck</surname><given-names>Mieke</given-names></name><xref ref-type="aff" rid="fcp12454-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="fcp12454-aff-0001">
<label><sup>1</sup></label>
<institution>Translational Oncology and Urology Research</institution>
<institution>King's College London</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><aff id="fcp12454-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Pharmacovigilance, Pharmacoepidemiology and Drug Information Center</named-content>
<institution>Rennes Hospital University</institution>
<city>Rennes</city>
<country country="FR">France</country>
</aff><aff id="fcp12454-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">REPERES (Pharmacoepidemiology and Heath Services Research)</named-content>
<institution>Rennes University</institution>
<postal-code>EA 7449, F&#x02010;35000</postal-code>
<city>Rennes</city>
<country country="FR">France</country>
</aff><aff id="fcp12454-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Centre for Public Health</named-content>
<institution>Institute for Health Sciences</institution>
<institution>Queen's University Belfast</institution>
<city>Belfast</city>
<country country="GB">Northern Ireland</country>
</aff><aff id="fcp12454-aff-0005">
<label><sup>5</sup></label>
<institution>Belgian Cancer Registry</institution>
<city>Brussels</city>
<country country="BE">Belgium</country>
</aff><aff id="fcp12454-aff-0006">
<label><sup>6</sup></label>
<institution>PHARMO Institute for Drug Outcomes Research</institution>
<city>Utrecht</city>
<country country="NL">The Netherlands</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>Correspondence and reprints: <email>gincy.e.george@kcl.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>3</month><year>2019</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2019</year></pub-date><volume>33</volume><issue>4</issue><issue-id pub-id-type="doi">10.1111/fcp.2019.33.issue-4</issue-id><fpage>479</fpage><lpage>499</lpage><history><date date-type="received"><day>09</day><month>4</month><year>2018</year></date><date date-type="rev-recd"><day>23</day><month>1</month><year>2019</year></date><date date-type="accepted"><day>15</day><month>2</month><year>2019</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2019 Soci&#x000e9;t&#x000e9; Fran&#x000e7;aise de Pharmacologie et de Th&#x000e9;rapeutique <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2019 The Authors. Fundamental &#x00026; Clinical Pharmacology published by John Wiley &#x00026; Sons Ltd on behalf of Soci&#x000e9;t&#x000e9; Fran&#x000e7;aisede Pharmacologie et de Th&#x000e9;rapeutique</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:FCP-33-479.pdf"/><abstract id="fcp12454-abs-0001"><title>Abstract</title><p>One of the more recently investigated adverse long&#x02010;term side effects of gonadotropin&#x02010;releasing hormone (Gn<styled-content style="fixed-case" toggle="no">RH</styled-content>) agonists for prostate cancer (<styled-content style="fixed-case" toggle="no">PC</styled-content>a) is cardiovascular disease (<styled-content style="fixed-case" toggle="no">CVD</styled-content>). Studies suggest lower risk of <styled-content style="fixed-case" toggle="no">CVD</styled-content> following Gn<styled-content style="fixed-case" toggle="no">RH</styled-content> antagonists (degarelix) than Gn<styled-content style="fixed-case" toggle="no">RH</styled-content> agonists. This protocol describes precise codes used to extract variables from five European databases for a study that compares risk of <styled-content style="fixed-case" toggle="no">CVD</styled-content> following Gn<styled-content style="fixed-case" toggle="no">RH</styled-content> agonists and antagonists for <styled-content style="fixed-case" toggle="no">PC</styled-content>a.</p><p>
<styled-content style="fixed-case" toggle="no">PC</styled-content>a men on primary Gn<styled-content style="fixed-case" toggle="no">RH</styled-content> agonists or antagonists were identified from the <styled-content style="fixed-case" toggle="no">UK THIN</styled-content> (The Health Improvement Network) database, National Health Service (<styled-content style="fixed-case" toggle="no">NHS</styled-content>) Scotland, Belgian Cancer Registry (<styled-content style="fixed-case" toggle="no">BCR</styled-content>), Dutch <styled-content style="fixed-case" toggle="no">PHARMO</styled-content> Database Network and French National Database (<styled-content style="fixed-case" toggle="no">SNIIRAM</styled-content>). Cohort entry was defined as date of treatment initiation. <styled-content style="fixed-case" toggle="no">CVD</styled-content> event was defined as any first incident or fatal <styled-content style="fixed-case" toggle="no">CVD</styled-content> after cohort entry. Readcodes in <styled-content style="fixed-case" toggle="no">THIN</styled-content> and <styled-content style="fixed-case" toggle="no">ICD</styled-content> codes in <styled-content style="fixed-case" toggle="no">NHS</styled-content> Scotland, <styled-content style="fixed-case" toggle="no">BCR</styled-content>,<styled-content style="fixed-case" toggle="no"> PHARMO</styled-content> and <styled-content style="fixed-case" toggle="no">SNIIRAM</styled-content> were used to extract variables. Risk of Bias in Non&#x02010;randomised studies of Interventions (<styled-content style="fixed-case" toggle="no">ROBINS</styled-content>&#x02010;I) tool was used to assess the potential risk of biases in this study. 51 572 men with a median follow&#x02010;up time of 2 years started on Gn<styled-content style="fixed-case" toggle="no">RH</styled-content> agonists and 2 417 men with a median follow&#x02010;up time of 1 year started on Gn<styled-content style="fixed-case" toggle="no">RH</styled-content> antagonists between 2010 and 2017 in the <styled-content style="fixed-case" toggle="no">UK</styled-content>, Scotland, Belgium, the Netherlands and France. Data from five countries improved the study power and internal validity required to compare risk of <styled-content style="fixed-case" toggle="no">CVD</styled-content> between Gn<styled-content style="fixed-case" toggle="no">RH</styled-content> agonists and antagonists, the latter being a fairly new drug with limited data in individual countries.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="fcp12454-kwd-0001">cardiovascular disease</kwd><kwd id="fcp12454-kwd-0002">Gn<styled-content style="fixed-case" toggle="no">RH</styled-content> agonists</kwd><kwd id="fcp12454-kwd-0003">Gn<styled-content style="fixed-case" toggle="no">RH</styled-content> antagonists</kwd><kwd id="fcp12454-kwd-0004">prostate cancer</kwd><kwd id="fcp12454-kwd-0005">real&#x02010;world evidence</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Ferring Pharmaceuticals </institution><institution-id institution-id-type="open-funder-registry">10.13039/501100003122</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="21"/><word-count count="10265"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>August 2019</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.1 mode:remove_FC converted:12.11.2019</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="fcp12454-ntgp-0001"><fn id="fcp12454-note-1001"><p>Joint first authors: Gincy George, Lucie&#x02010;Marie Scailteux.</p></fn></fn-group></notes></front><body id="fcp12454-body-0001"><sec id="fcp12454-sec-0001"><title>Introduction</title><p>Prostate cancer (PCa) is the most common cancer among men in Europe, with a further increase in projected incidence rates <xref rid="fcp12454-bib-0001" ref-type="ref">1</xref>, <xref rid="fcp12454-bib-0002" ref-type="ref">2</xref>. By decreasing male hormone levels, androgen deprivation therapy (ADT) serves as the mainstream treatment for symptomatic PCa. More specifically, ADT is commonly used in men with biochemical relapse after radical prostatectomy (RP), locally advanced PCa and metastasis <xref rid="fcp12454-bib-0003" ref-type="ref">3</xref>, <xref rid="fcp12454-bib-0004" ref-type="ref">4</xref>.</p><p>Several metabolic side effects have been reported for ADT, including increased body weight, insulin resistance, dyslipidaemia and hyperglycaemia <xref rid="fcp12454-bib-0005" ref-type="ref">5</xref>, <xref rid="fcp12454-bib-0006" ref-type="ref">6</xref>, <xref rid="fcp12454-bib-0007" ref-type="ref">7</xref>, <xref rid="fcp12454-bib-0008" ref-type="ref">8</xref>. One of the more recently investigated side effects of ADT is an increased risk of cardiovascular diseases (CVD), which is believed to be due to a reduced cardio&#x02010;protective effect of testosterone <xref rid="fcp12454-bib-0006" ref-type="ref">6</xref>, <xref rid="fcp12454-bib-0009" ref-type="ref">9</xref>, <xref rid="fcp12454-bib-0010" ref-type="ref">10</xref>, <xref rid="fcp12454-bib-0011" ref-type="ref">11</xref>, <xref rid="fcp12454-bib-0012" ref-type="ref">12</xref>. In 2010, the findings from several observational studies <xref rid="fcp12454-bib-0006" ref-type="ref">6</xref>, <xref rid="fcp12454-bib-0009" ref-type="ref">9</xref>, <xref rid="fcp12454-bib-0010" ref-type="ref">10</xref>, <xref rid="fcp12454-bib-0011" ref-type="ref">11</xref>, <xref rid="fcp12454-bib-0012" ref-type="ref">12</xref>, <xref rid="fcp12454-bib-0013" ref-type="ref">13</xref>, <xref rid="fcp12454-bib-0014" ref-type="ref">14</xref> prompted the Food and Drug Administration (FDA) to issue a new requirement for manufacturers of certain types of ADT (gonadotropin&#x02010;releasing hormone (GnRH) receptor agonists) to add safety information to drug labels in order to warn users of the potential CVD risks involved.</p><p>It is therefore of interest to note that degarelix, a newly introduced GnRH receptor antagonist (2010), was suggested to be associated with a lower risk of CVD in PCa men <xref rid="fcp12454-bib-0015" ref-type="ref">15</xref>, <xref rid="fcp12454-bib-0016" ref-type="ref">16</xref>. These observations were also supported by preclinical mouse models showing less atherosclerosis and characteristics of metabolic syndrome in mice treated with degarelix as compared to those with orchiectomy or GnRH agonists <xref rid="fcp12454-bib-0017" ref-type="ref">17</xref>. Even though a recent systematic review <xref rid="fcp12454-bib-0018" ref-type="ref">18</xref> suggested that GnRH antagonists may be appropriate for those men with significant CVD risk, existing osteopenia, lower urinary tract symptoms and significant metastatic disease, no results from randomized clinical trials (RCTs) are available to compare the risk of CVD between GnRH agonists and antagonists. The PRONOUNCE trial (ClinicalTrials.gov identifier: NCT02663908), a phase III RCT comparing CVD safety of leuprolide (GnRH agonist) and degarelix (GnRH antagonist), is currently recruiting patients with an anticipated completion date in December 2020 <xref rid="fcp12454-bib-0019" ref-type="ref">19</xref>. An observational study, which directly compared the risk of CVD between GnRH antagonists and GnRH agonists, detected no difference in risk of developing stroke and myocardial infarction (MI). However, overall CVD was not investigated as a specific outcome <xref rid="fcp12454-bib-0020" ref-type="ref">20</xref>.</p><p>Even though the results of the PRONOUNCE trial will inform the long&#x02010;term side effects of GnRH analogues, it is equally important that any results obtained are applicable to the general PCa population. Observational studies, when well conducted, provide similar estimates of side effects to RCTs &#x02013; which is the rationale behind phase IV studies <xref rid="fcp12454-bib-0021" ref-type="ref">21</xref>. Elderly participants and those with comorbidities, two common characteristics of PCa patients receiving ADT, are often excluded from RCTs <xref rid="fcp12454-bib-0022" ref-type="ref">22</xref>.</p><p>Therefore, we designed a study using real&#x02010;world evidence from five countries to provide results that are more applicable to the general PCa population. Moreover, as degarelix was only licensed in 2010, there was a need to combine data from different countries (the United Kingdom (UK), Scotland, Belgium, the Netherlands and France) to obtain a sufficient sample size. Preliminary results of this study were presented at the Annual Meeting of the European Association of Urology, 2018 <xref rid="fcp12454-bib-0023" ref-type="ref">23</xref> and the Global Cardio&#x02010;Oncology Summit, 2018 <xref rid="fcp12454-bib-0024" ref-type="ref">24</xref>.</p><p>This study describes a methodological protocol which accounts for heterogeneity in the five databases by making study variables and analyses as homogenous as possible. In this protocol, we describe the codes used to extract study variables from the databases and the processes and challenges encountered in collecting and analysing real&#x02010;world data. When designing the protocol for this observational study, we followed the design of a target trial to assess all potential biases by using the Risk Of Bias In Non&#x02010;randomised Studies &#x02010; of Interventions (ROBINS&#x02010;I) tool <xref rid="fcp12454-bib-0025" ref-type="ref">25</xref>.</p></sec><sec id="fcp12454-sec-0002"><title>Materials and methods</title><sec id="fcp12454-sec-0003"><title>Study design</title><p>To investigate the association between GnRH agonists or GnRH antagonists and risk of CVD, we designed a prospective cohort study using databases (described in the &#x02018;databases&#x02019; section below) from the UK, Scotland, Belgium, the Netherlands and France. The protocol was designed to obtain country&#x02010;specific hazard ratios (stage 1), which were pooled in a meta&#x02010;analysis (stage 2).</p><sec id="fcp12454-sec-0004"><title>Target trial</title><p>A target trial is a pragmatic trial that emulates a hypothetical RCT in non&#x02010;randomized studies of interventions (NRSIs) and can thus be considered useful when designing an observational study to assess effects of different types of drugs. The results of NRSIs can be evaluated for any risk of bias (RoB) by using the ROBINS&#x02010;I tool <xref rid="fcp12454-bib-0025" ref-type="ref">25</xref>. The latter is based on seven specific bias domains that address biases at pre&#x02010;intervention, during intervention and after intervention <xref rid="fcp12454-bib-0025" ref-type="ref">25</xref>. To ensure a clinically applicable study design for our real&#x02010;world study, we used a modified version of the ROBINS&#x02010;I tool to emulate a target trial for risk of CVD following GnRH agonists or GnRH antagonists in men with PCa.</p></sec></sec><sec id="fcp12454-sec-0005"><title>Study population</title><p>Men with PCa entered the cohort on the date of treatment (GnRH agonists or GnRH antagonists) initiation. In addition to exposure variable, cohort entry was also determined by the presence of advanced or metastatic PCa where stage of PCa was available (Belgium and the Netherlands). Once an individual entered the cohort, they stayed on that treatment regime until time of censoring.</p><sec id="fcp12454-sec-0006"><title>Databases</title><sec id="fcp12454-sec-0007"><title>The health improvement network</title><p>The Health Improvement Network (THIN) database is an electronic database that covers more than 11 million patients in the UK and is representative of 6.2% of the UK population <xref rid="fcp12454-bib-0026" ref-type="ref">26</xref>, <xref rid="fcp12454-bib-0027" ref-type="ref">27</xref>. The database comprises of longitudinal, anonymized data processed and validated by Cegedim Strategic Data (CSD) Medical Research UK. THIN is organized into seven different files (<italic>Figure</italic>
<xref rid="fcp12454-fig-0001" ref-type="fig">1</xref>
<italic>),</italic> which are extracted from general practices (GP) in the UK using the VISION <xref rid="fcp12454-bib-0028" ref-type="ref">28</xref> system. The data are coded using standardized codes called the &#x02018;readcodes&#x02019; <xref rid="fcp12454-bib-0029" ref-type="ref">29</xref> or &#x02018;medcodes&#x02019; and &#x02018;drugcodes&#x02019;. As some individuals may be present in both THIN and National Health Service (NHS) Scotland databases, PCa men from Scotland were excluded from THIN. The study period used for this project extended from 2010 to 2016.</p><fig fig-type="Figure" xml:lang="en" id="fcp12454-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Organization of data in the <styled-content style="fixed-case" toggle="no">THIN</styled-content> database.</p></caption><graphic id="nlm-graphic-1" xlink:href="FCP-33-479-g001"/></fig></sec><sec id="fcp12454-sec-0008"><title>National health service Scotland</title><p>Data were linked from five databases in Scotland <xref rid="fcp12454-bib-0030" ref-type="ref">30</xref>: the Scottish Cancer Registry, the Scottish National Prescribing Information System (PIS), the General or Acute Inpatient and Day Case dataset (SMR01), the Outpatient Attendance dataset (SMR00) and the National Records of Scotland Death Records (NRSDR) using the unique identifier number, Community Health Index Number. The resulting dataset captures information on PCa diagnosis and treatment (from the Scottish Cancer Registry), community prescriptions in Scotland (PIS), hospital diagnoses and operations (SMR01), diagnoses and procedures from outpatient clinics (SMR00) and the date and cause of death (NRSDR) <xref rid="fcp12454-bib-0030" ref-type="ref">30</xref>. Men diagnosed with PCa from 2010 to 2015 with follow&#x02010;up until 2017 were part of this study.</p></sec><sec id="fcp12454-sec-0009"><title>Belgian cancer registry</title><p>All new cancer cases are legally required to be registered in Belgium in the Belgian Cancer Registry (BCR) <xref rid="fcp12454-bib-0031" ref-type="ref">31</xref>. The database constitutes of population&#x02010;based clinical&#x02013;pathological information on new cancer diagnoses with almost complete coverage of the Belgian population since 2004. Administrative data on reimbursed medical acts and dispensed in&#x02010; and outpatient medications are provided to the BCR by the health insurance companies (HIC), covering a period from 1 year before until 5 years after the date of cancer diagnosis <xref rid="fcp12454-bib-0032" ref-type="ref">32</xref>. The HIC data contain information regarding the date and type of charged diagnostic and therapeutic procedures, and regarding the date, amount and dosages of dispensed medications. Following specific authorizations, hospital discharge data (HDD) covering hospitalizations of the patients registered by BCR from the year prior to the incidence date onwards are made available using specific codes <xref rid="fcp12454-bib-0033" ref-type="ref">33</xref>. These records contain information on hospital admission and discharge dates, diagnoses and procedures for each hospitalization. Both HIC and HDD data are deterministically coupled to the BCR database, using the national social security number as a unique patient identifier. Cause of death information for all Belgian inhabitants is provided by the three different Belgian regions and probabilistically coupled to the BCR data (coupling percentage 98%). The current project used data from 2010 to 2013.</p></sec><sec id="fcp12454-sec-0010"><title>PHARMO Database Network</title><p>The PHARMO Database Network is a population&#x02010;based network of healthcare databases combining data from both primary and secondary healthcare settings in the Netherlands <xref rid="fcp12454-bib-0034" ref-type="ref">34</xref>. These different data sources, including data from GPs, in&#x02010; and outpatient pharmacies, clinical laboratories, hospitals, the cancer registry, pathology registry and perinatal registry, are linked on a patient level through validated algorithms. Detailed information on the methodology and the validation of the used record linkage method can be found elsewhere <xref rid="fcp12454-bib-0035" ref-type="ref">35</xref>. For this study, data from the Out&#x02010;patient Pharmacy Database, Hospitalisation Database and Cancer Registry were used. The Out&#x02010;patient Pharmacy Database includes detailed information on GP or specialist prescribed healthcare products dispensed by outpatient pharmacies. The dispensing records include information on type of product, date, strength and dosage regimen, quantity, route of administration, prescriber specialty and costs. The Hospitalisation Database comprises of hospital admissions for more than 24 hours and admissions for less than 24 hours, for which a bed was required (i.e. inpatient records) from the Dutch Hospital Data Foundation. The records include information on hospital admission and discharge dates, discharge diagnoses and procedures. The Cancer Registry comprises information on newly diagnosed cancer patients in the Netherlands <xref rid="fcp12454-bib-0034" ref-type="ref">34</xref>. For the current project, we used data from 2010 to 2015.</p></sec><sec id="fcp12454-sec-0011"><title>French Health National Database (SNIIRAM)</title><p>The French Health National Database based on claims data called the Syst&#x000e8;me National d'Informations Inter&#x02010;R&#x000e9;gimes de l'Assurance Maladie (SNIIRAM) was used for this study <xref rid="fcp12454-bib-0036" ref-type="ref">36</xref>. SNIIRAM combines reimbursed claims from insurance plans with the National Hospital discharge Summaries database system (PMSI). As of 2016, the SNIIRAM includes 98.8% of the French population with follow&#x02010;up from birth to death <xref rid="fcp12454-bib-0037" ref-type="ref">37</xref>. The database includes information on patient demographics, hospital and clinical visits, diagnoses of hospitalized patients (extracted using ICD&#x02010;10 codes from hospital visits) and chronic medical conditions. Data between 2010 and 2013 were used for this study.</p></sec></sec></sec><sec id="fcp12454-sec-0012"><title>Study variables</title><sec id="fcp12454-sec-0013"><title>Exposure variable</title><p>The exposure variable was defined as prescription or dispensation of GnRH agonists or GnRH antagonists. PCa men who were hormone&#x02010;treatment na&#x000ef;ve were followed from date of first prescription or dispensation until censoring (defined below).</p></sec><sec id="fcp12454-sec-0014"><title>Outcome variables</title><p>The outcome variable was defined as first (incident or fatal) CVD event (ICD&#x02010;10: I20&#x02010;I99, G45 or ICD&#x02010;9 equivalent) following GnRH agonists or antagonists initiation. In addition to overall CVD, the following five types of CVD were considered: ischaemic heart disease (IHD) (ICD&#x02010;10: I20&#x02010;I25), acute myocardial infarction (AMI) (ICD&#x02010;10: I21), arrhythmia (ICD&#x02010;10: I44&#x02010;I49), heart failure (HF) (ICD&#x02010;10: I50, I97.710, I97.790, I11.0) and stroke (ICD&#x02010;10: I60&#x02010;64, G45). The THIN database made use of already published readcodes <xref rid="fcp12454-bib-0029" ref-type="ref">29</xref> similar to the ICD codes.</p></sec><sec id="fcp12454-sec-0015"><title>Censoring</title><p>The censoring point was defined as any of the first occurring among the following: outcome, switch between GnRH agonists and antagonists and vice versa, orchiectomy, end of study period or death from other causes than CVD death during the study period, whichever came first. Since the six CVD outcomes were studied separately, only the first event of the interested outcome at the time of analysis was considered. For example, when IHD was studied as an outcome, men were censored at first incident or fatal IHD. Any CVD, AMI, arrhythmia, heart failure and stroke after treatment initiation were overlooked, even if these had occurred before the IHD event.</p></sec><sec id="fcp12454-sec-0016"><title>Other study variables</title><sec id="fcp12454-sec-0017"><title>Age</title><p>Age was considered as a timescale in all analytical models and was defined at date of GnRH agonists or antagonists' initiation. 5 562 men in THIN had missing date of births which were imputed using multiple imputation. Age for all men in PHARMO was calculated using the same random day and month (12th June) as it only contained the year of birth.</p></sec><sec id="fcp12454-sec-0018"><title>Follow&#x02010;up time</title><p>The median follow&#x02010;up time and upper and lower quartiles were calculated for all countries. Follow&#x02010;up time began on the date of treatment initiation and ended when they reached any of the censoring criteria discussed above.</p></sec><sec id="fcp12454-sec-0019"><title>Year of PCa diagnosis</title><p>Year of PCa diagnosis was extracted for all countries except for France, where data for the year of PCa diagnosis was not available.</p></sec><sec id="fcp12454-sec-0020"><title>Stage of PCa</title><p>PCa stage was available for Scotland, Belgium and the Netherlands, recorded at the time of PCa diagnosis. It was defined as locally advanced (T3a/bT4 N0M0) and metastatic (TxNxM1), as most men with PCa on long&#x02010;term GnRH analogues are categorized into these stages. Further PCa stage subgroups were distinguished as: TxNxM1, TxN1M0, T3aNxMx, T3bNxMx and T4NxMx in Belgium.</p></sec><sec id="fcp12454-sec-0021"><title>Total Gleason Score</title><p>Total Gleason Score (GS) was available for Scotland and the Netherlands and was divided into Gleason 5&#x02013;6, 7, 8, 9&#x02013;10 and missing. In the Netherlands, men with invalid GS (nine patients) were included in the missing category.</p></sec><sec id="fcp12454-sec-0022"><title>Prostate&#x02010;specific antigen</title><p>Prostate&#x02010;specific antigen (PSA), only available for the Netherlands, was categorized into &#x02264; 10, 11&#x02013;20, 21&#x02013;50 and &#x0003e; 50 ng/mL.</p></sec><sec id="fcp12454-sec-0023"><title>Any prior PCa treatment</title><p>Some information on PCa treatment before GnRH initiation was available for all five countries. This included men who had undergone any form of PCa treatment prior to GnRH initiation such as radical prostatectomy, radical prostatectomy and adjuvant or salvage radiotherapy (Belgium only), radiotherapy, chemotherapy (the Netherlands only) and anti&#x02010;androgens. In Belgium, radiotherapy was further split into palliative radiotherapy (1&#x02013;10 fractions) and long course external beam radiotherapy (+/&#x02010; brachytherapy).</p></sec><sec id="fcp12454-sec-0024"><title>Type of ADT</title><p>This variable indicated whether ADT (only in the form of GnRH agonists or antagonists) was given as primary, adjuvant, neo&#x02010;adjuvant treatment or other (Belgium only). No distinction between primary, neo&#x02010;adjuvant and adjuvant ADT was made in the UK due to a lack of accurate data availability on radiotherapy given to men on ADT. An ADT prescription in Belgium and Scotland was considered neo&#x02010;adjuvant if it appeared in the database within 1 month before PCa incidence and the date of surgery or radiotherapy. An adjuvant ADT prescription was defined as a prescription of GnRH agonists or antagonists within a 6 months' period following surgery or radiotherapy. PCa men for whom a treatment (ADT) was found but had not fulfilled the definitions of primary, adjuvant or neo&#x02010;adjuvant ADT treatment (e.g. ADT treatment started more than 6 months following surgery) were classed into the &#x02018;other&#x02019; category. In the Netherlands, the cancer registry only had treatment information given at PCa diagnosis and 6 months after diagnosis and combination treatment modalities were not derived for the study. In France, information for radiotherapy (especially dosages) was not available, and therefore, a distinction between primary, adjuvant and neo&#x02010;adjuvant was not made.</p></sec><sec id="fcp12454-sec-0025"><title>ADT specifics</title><p>This variable showed whether ADT was prescribed in combination with anti&#x02010;androgens as flare protection or combined androgen blockade (CAB). Flare protection was defined as receiving anti&#x02010;androgens for &#x02264; 30 days, whereas CAB was defined as receiving anti&#x02010;androgens for more than 30 days.</p></sec><sec id="fcp12454-sec-0026"><title>History of CVD indicator</title><p>History of CVD indicator (HCVDi) was defined as any of the following 12 months prior to entering the cohort: any CVD event (ICD&#x02010;10 codes: I20&#x02010;I99, G45), hypertension (ICD&#x02010;10 and ATC codes &#x02013; <italic>Figure</italic>
<xref rid="fcp12454-fig-0002" ref-type="fig">2</xref>), dyslipidaemia (ATC codes or drugcodes &#x02013; <italic>Table III</italic>) or diabetes (ATC codes or drugcodes &#x02013; <italic>Table III</italic>). HCVDi was further subcategorized to specifically indicate history of hypertension, dyslipidaemia or diabetes 12 months prior to ADT initiation.</p><fig fig-type="Figure" xml:lang="en" id="fcp12454-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Algorithm to define hypertension (<styled-content style="fixed-case" toggle="no">HTA</styled-content>) used by France and the Netherlands (Panel 1) and modified algorithm used by Belgium (Panel 2).</p></caption><graphic id="nlm-graphic-3" xlink:href="FCP-33-479-g002"/></fig></sec><sec id="fcp12454-sec-0027"><title>Number of previous CVD events</title><p>The number of CVD events prior to entering the cohort was coded as 0, 1, 2 or &#x02265; 3 CVD events. As data in Belgium were only available 1 year before first ADT prescription, previous CVD events and time of last previous CVD were limited to the 12 months prior to entering the cohort. The previous history of CVD was stratified as time of last previous CVD, defined as no CVD, 0&#x02013;3 months, 4&#x02013;6 months, 7&#x02013;12 months prior to treatment initiation.</p></sec><sec id="fcp12454-sec-0028"><title>Socio&#x02010;demographic variables</title><p>Body mass index (BMI), socio&#x02010;economic status (SES), civil status, smoking status and ethnicity were extracted in the UK using the readcodes (<italic>Table II</italic> for specific codes). BMI was defined as: underweight at &#x02264; 18.5 kg/m<sup>2</sup>, normal at 18.6&#x02013;24 kg/m<sup>2</sup>, overweight at 25&#x02013;30 kg/m<sup>2</sup> and obese at &#x02265; 30 kg/m<sup>2</sup>. Townsend scores <xref rid="fcp12454-bib-0038" ref-type="ref">38</xref> were used to extract the SES of the study population. Townsend scores incorporated four different variables: unemployment, non&#x02010;car ownership, non&#x02010;home ownership and household overcrowding. The Townsend scores were given as quintiles (i.e. five groups of equal size ranging from 1 (least deprived) to 5 (most deprived) <xref rid="fcp12454-bib-0038" ref-type="ref">38</xref>). In THIN, civil status was coded as 12 different codes that were combined to form three categories: single, married and unknown (<italic>Table II</italic>). Smoking status was defined as: current smokers, non&#x02010;smokers and past smokers. Ethnicity was defined as men with an origin of: Caucasian, Black, Asian and other (readcodes other than these three categories).</p></sec></sec></sec><sec id="fcp12454-sec-0029"><title>Analysis</title><p>The analysis was conducted in two stages: stage 1 analysis was used to assess heterogeneity and prescription patterns in different countries and stage 2 was a pooled analysis of PCa cohorts from five countries using meta&#x02010;analytical techniques to pool the results. Results of the meta&#x02010;analysis will be reported in the main study article.</p><sec id="fcp12454-sec-0030"><title>Stage 1 analysis</title><p>Country&#x02010;specific estimates of hazard ratios were calculated using Cox proportional hazard models with age as a timescale. When using age as a timescale, men entered the cohort at baseline age (left&#x02010;truncation) and exited at CVD event age or censoring age. Stage 1 analysis was conducted in four separate steps: (i) age&#x02010;adjusted analysis with CVD as outcome, (ii) stratified analysis based on HCVDi, (iii) multivariable analysis including HCVDi and (iv) multivariable analysis including HCVDi and number of previous CVD events.</p></sec><sec id="fcp12454-sec-0031"><title>Stage 2 analysis</title><p>In the second stage, a random&#x02010;effects meta&#x02010;analytic model was performed to compare the pooled log&#x02010;transformed country&#x02010;specific hazard ratios for CVD following GnRH agonists and GnRH antagonists. The percentage of variation between the databases was assessed using the <italic>I</italic>
<sup>2</sup> statistic. Each country in the meta&#x02010;analysis was weighted by the inverse of its variance (i.e. hazard ratios), and adjustment to the weight was made based upon the degree of heterogeneity between the five countries. Heterogeneity in the assessment of exposure and outcome data was further evaluated by performing sensitivity analyses. This included only those countries that had collected data in a similar way &#x02013; incident CVD (ICD&#x02010;9&#x02010;CM codes) sourced from hospital discharge date and fatal CVD (ICD&#x02010;10 codes) sourced from death certificates in Belgium, ICD&#x02010;10 codes in Scotland, the Netherlands and France versus readcodes in the UK. Additional stratifications by HCVDi as well as age (&#x0003c; 75 and &#x02265; 75 years) were conducted to assess effect modification in all countries.</p></sec></sec></sec><sec id="fcp12454-sec-0032"><title>Results</title><p>
<italic>Table</italic>
<xref rid="fcp12454-tbl-0001" ref-type="table">1</xref> shows the modified ROBINS&#x02010;I tool used to compare a target trial with this study. This informed the inclusion/exclusion criteria for the real&#x02010;world study population as well as the definitions of all relevant exposures, outcomes and study variables. The aim of using the ROBINS&#x02010;I tool was to understand the types of biases and challenges involved when dealing with real&#x02010;world, heterogeneous data sources. The ROBINS&#x02010;I tool highlighted unmeasured confounding, channelling and misclassification biases.</p><table-wrap id="fcp12454-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Target trial using ROBINS&#x02010;I <xref rid="fcp12454-bib-0025" ref-type="ref">25</xref> tool</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Types of bias addressed</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Trial characteristics</th><th align="left" rowspan="2" valign="top" colspan="1">Challenges encountered</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Target trial</th><th align="left" valign="top" rowspan="1" colspan="1">This study</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Randomization distribution</td><td align="left" rowspan="1" colspan="1">50/50 split</td><td align="left" rowspan="1" colspan="1">Uneven number of patients in GnRH agonists and GnRH antagonists</td><td align="left" rowspan="1" colspan="1">Observational data do not guarantee even distribution between trial arms</td></tr><tr><td align="left" rowspan="1" colspan="1">Information bias</td><td align="left" rowspan="1" colspan="1">Information on compliance to treatment</td><td align="left" rowspan="1" colspan="1">An individual is assumed to be in the same cohort at end of study as they are in at start of the study</td><td align="left" rowspan="1" colspan="1">There is no information on compliance in most observational databases</td></tr><tr><td align="left" rowspan="1" colspan="1">Unmeasured confounding</td><td align="left" rowspan="1" colspan="1">Lifestyle and socio&#x02010;demographic factors</td><td align="left" rowspan="1" colspan="1">Information used for lifestyle and socio&#x02010;demographic variables</td><td align="left" rowspan="1" colspan="1">Lifestyle factors are often not well recorded in healthcare databases leading to an unmeasured confounding. The UK was the only country with data on some lifestyle (BMI, smoking status) and socio&#x02010;economic (Townsend scores) factors recorded. However, due to high missing data, these variables were not added to the analytical models</td></tr><tr><td align="left" rowspan="1" colspan="1">Unmeasured confounding</td><td align="left" rowspan="1" colspan="1">Concomitant medications, history of specific diseases</td><td align="left" rowspan="1" colspan="1">History of CVD indicator</td><td align="left" rowspan="1" colspan="1">Although CVD risk factors such as HTN, DM and DYS were adjusted for in HCVDi, there may be other unmeasured concomitant medications that we may not have taken into account, leading to unmeasured confounding. This will be addressed in the main study article by calculating E&#x02010;values to assess the strength of unmeasured confounding in our study</td></tr><tr><td align="left" rowspan="1" colspan="1">Channeling bias</td><td align="left" rowspan="1" colspan="1">GnRH antagonists to patients with no history of CVD</td><td align="left" rowspan="1" colspan="1">Men with a history of CVD may be prescribed GnRH antagonists</td><td align="left" rowspan="1" colspan="1">GnRH antagonists may have been preferentially &#x02018;channeled&#x02019; to patients who may have been at risk of a CVD leading to a channeling bias. This has to be considered when interpreting the results of this study</td></tr><tr><td align="left" rowspan="1" colspan="1">Classification bias</td><td align="left" rowspan="1" colspan="1">Uniform coding system to define exposure and outcome variables</td><td align="left" rowspan="1" colspan="1">Readcodes &#x00026; drugcodes for UK and ATC codes &#x00026; ICD codes for Scotland, Belgium, the Netherlands and France</td><td align="left" rowspan="1" colspan="1">It was difficult to homogenize the coding system fully across the five countries in this study, due to heterogeneity in the data collection methods</td></tr><tr><td align="left" rowspan="1" colspan="1">Immortal time bias</td><td align="left" rowspan="1" colspan="1">Information on GnRH agonists and GnRH antagonists dispensation</td><td align="left" rowspan="1" colspan="1">Prescription database in the UK. Dispensing database in Scotland, Belgium, the Netherlands and France</td><td align="left" rowspan="1" colspan="1">Prescription databases usually do not hold information on whether the patient has adhered to their prescribed treatment. For example, a man with PCa may be prescribed GnRH antagonists on 1<sup>st</sup> November but may not visit their health care professional on the same day for their injection. This introduces a lag time between the prescription date and dispensation/injection date resulting in an immortal time bias. A sensitivity analysis excluding the UK accounted for immortal time bias</td></tr><tr><td align="left" rowspan="1" colspan="1">Immeasurable time bias</td><td align="left" rowspan="1" colspan="1">Medications given at hospital visits during the follow&#x02010;up time</td><td align="left" rowspan="1" colspan="1">Hospital data were not available for the UK and medications from the inpatient pharmacy was not available for France and the Netherlands</td><td align="left" rowspan="1" colspan="1">Immeasurable time bias arises from the presence of an unidentified hospitalization within a database <xref rid="fcp12454-bib-0049" ref-type="ref">49</xref>. Records of medications administered during a hospital visit may not have been available during the study period. Data for unidentified hospitalization were not available in the five countries</td></tr></tbody></table><table-wrap-foot id="fcp12454-ntgp-0002"><fn id="fcp12454-note-0002"><p>HTN, Hypertension; DYS, dyslipidaemia; DM, diabetes mellitus.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>
<italic>Table</italic>
<xref rid="fcp12454-tbl-0002" ref-type="table">2</xref> shows the study period, number of men with PCa on GnRH agonists and antagonists and follow&#x02010;up time (median and quartiles) for the UK, Scotland, Belgium, the Netherlands and France. Total median follow&#x02010;up time for the UK, Scotland, Belgium, the Netherlands and France was 2 (1.1&#x02013;2.8) years for GnRH agonists and 1 (0.7&#x02013;1.8) year for GnRH antagonists. High missing numbers for socio&#x02010;demographic confounders (BMI, SES, smoking status and civil status) resulted in an exclusion of these variables from the analytical models. <italic>Table</italic>
<xref rid="fcp12454-tbl-0003" ref-type="table">3</xref> shows detailed codes used to extract study variables from four databases.</p><table-wrap id="fcp12454-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Study period, number of men with prostate cancer on GnRH agonists and antagonists, and median follow&#x02010;up time five European databases: the United Kingdom, Scotland, Belgium, the Netherlands and France</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" valign="top" colspan="1"/><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">United Kingdom (excluding Scotland)</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Scotland</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Belgium</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Netherlands</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">France</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Men on GnRH agonists</th><th align="left" valign="top" rowspan="1" colspan="1">Men on GnRH antagonists</th><th align="left" valign="top" rowspan="1" colspan="1">Men on GnRH agonists</th><th align="left" valign="top" rowspan="1" colspan="1">Men on GnRH antagonists</th><th align="left" valign="top" rowspan="1" colspan="1">Men on GnRH agonists</th><th align="left" valign="top" rowspan="1" colspan="1">Men on GnRH antagonists</th><th align="left" valign="top" rowspan="1" colspan="1">Men on GnRH agonists</th><th align="left" valign="top" rowspan="1" colspan="1">Men on GnRH antagonists</th><th align="left" valign="top" rowspan="1" colspan="1">Men on GnRH agonists</th><th align="left" valign="top" rowspan="1" colspan="1">Men on GnRH antagonist</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">N (%)</th><th align="left" valign="top" rowspan="1" colspan="1">N (%)</th><th align="left" valign="top" rowspan="1" colspan="1">N (%)</th><th align="left" valign="top" rowspan="1" colspan="1">N (%)</th><th align="left" valign="top" rowspan="1" colspan="1">N (%)</th><th align="left" valign="top" rowspan="1" colspan="1">N (%)</th><th align="left" valign="top" rowspan="1" colspan="1">N (%)</th><th align="left" valign="top" rowspan="1" colspan="1">N (%)</th><th align="left" valign="top" rowspan="1" colspan="1">N (%)</th><th align="left" valign="top" rowspan="1" colspan="1">N (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Study period</td><td align="left" colspan="2" rowspan="1">2010&#x02010;2016</td><td align="left" colspan="2" rowspan="1">2010&#x02010;2017</td><td align="left" colspan="2" rowspan="1">2010&#x02010;2015</td><td align="left" colspan="2" rowspan="1">2010&#x02010;2015</td><td align="left" colspan="2" rowspan="1">2010&#x02010;2013</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of PCa men</td><td align="left" rowspan="1" colspan="1">16 955 (99.3)</td><td align="left" rowspan="1" colspan="1">118 (0.7)</td><td align="left" rowspan="1" colspan="1">11 929 (94.0)</td><td align="left" rowspan="1" colspan="1">768 (6.0)</td><td align="left" rowspan="1" colspan="1">1 860 (78.1)</td><td align="left" rowspan="1" colspan="1">522 (21.9)</td><td align="left" rowspan="1" colspan="1">1 187 (92.5)</td><td align="left" rowspan="1" colspan="1">97 (7.6)</td><td align="left" rowspan="1" colspan="1">19 641 (83.9)</td><td align="left" rowspan="1" colspan="1">912 (3.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Follow&#x02010;up time, years</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">0.8</td><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">2.4</td><td align="left" rowspan="1" colspan="1">2.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Lower quartile</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">0.1</td><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">0.8</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">1.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Upper quartile</td><td align="left" rowspan="1" colspan="1">1.8</td><td align="left" rowspan="1" colspan="1">1.2</td><td align="left" rowspan="1" colspan="1">2.9</td><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">3.0</td><td align="left" rowspan="1" colspan="1">1.8</td><td align="left" rowspan="1" colspan="1">3.4</td><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="1" colspan="1">2.7</td><td align="left" rowspan="1" colspan="1">2.6</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><table-wrap id="fcp12454-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Codes used for the databases from the UK, France, Belgium and the Netherlands to extract study variables</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Variables</th><th align="left" rowspan="2" valign="top" colspan="1">Definitions</th><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Codes used</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">United Kingdom</th><th align="left" valign="top" rowspan="1" colspan="1">France</th><th align="left" valign="top" rowspan="1" colspan="1">Belgium<xref ref-type="fn" rid="fcp12454-note-0003">a</xref>
</th><th align="left" valign="top" rowspan="1" colspan="1">Netherlands</th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1">Exposures defined by drugcodes in UK and ATC codes in France, Belgium and the Netherlands</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">GnRH agonists</td><td align="left" rowspan="1" colspan="1">Prescription or dispensation of: Leuprorelin Acetate (Eligard), Leuprorelin Acetate (Lucrin), Leuprorelin Acetate (Generics)</td><td align="left" rowspan="1" colspan="1">Drugcodes: 39797978, 42604978, 61916979, 61917979, 61918979, 61919979, 88842998, 88845998, 92404979, 92405979, 92412979, 96945998, 97368998, 81332998, 81333998</td><td align="left" rowspan="1" colspan="1">ATC: L02AE02</td><td align="left" rowspan="1" colspan="1">ATC: L02AE02</td><td align="left" rowspan="1" colspan="1">ATC: L02AE02</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Prescription or dispensation of: Goserelin (Zoladex)</td><td align="left" rowspan="1" colspan="1"> Drugcodes: 82646998, 91057998, 91058998, 92434979, 92436979, 92439979, 92444979, 94894998, 94895998</td><td align="left" rowspan="1" colspan="1">ATC: L02AE03</td><td align="left" rowspan="1" colspan="1">ATC: L02AE03</td><td align="left" rowspan="1" colspan="1">ATC: L02AE03</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Prescription or dispensation of: Buserelin</td><td align="left" rowspan="1" colspan="1">Drugcodes: 94133997, 94133998, 97430997, 97430998</td><td align="left" rowspan="1" colspan="1">ATC: L02AE02</td><td align="left" rowspan="1" colspan="1">ATC: L02AE02</td><td align="left" rowspan="1" colspan="1">ATC: L02AE02</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Triptorelin (Decapeptyl or Gonapeptyl Depot)</td><td align="left" rowspan="1" colspan="1">Drugcodes: 81648998, 81649998, 81699998, 81700998, 87670998, 87671998, 87744998, 87745998, 91336998, 91337998</td><td align="left" rowspan="1" colspan="1">ATC: L02AE04</td><td align="left" rowspan="1" colspan="1">ATC: L02AE04</td><td align="left" rowspan="1" colspan="1">ATC: L02AE04</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">GnRH antagonist</td><td align="left" rowspan="1" colspan="1">Prescription or dispensation of: Degarelix</td><td align="left" rowspan="1" colspan="1">Drugcodes: 82881998, 82882998, 82886998, 82887998</td><td align="left" rowspan="1" colspan="1">ATC: L02BX02</td><td align="left" rowspan="1" colspan="1">ATC: L02BX02</td><td align="left" rowspan="1" colspan="1">ATC: L02BX02</td></tr><tr><td align="left" colspan="6" rowspan="1">Outcomes defined by readcodes in UK and ICD codes in France, Belgium and the Netherlands</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Any CVD</td><td align="left" rowspan="1" colspan="1">First incident or fatal any CVD</td><td align="left" rowspan="1" colspan="1">G3&#x02026;00, G3&#x02026;11, G3&#x02026;12, G3&#x02026;13, G30..00, G30..12, G30..13, G30..15, G30..16, G30..17, G300.00, G301.00, G301000, G301100, G301z00, G302.00, G303.00, G304.00, G305.00, G306.00, G307.00, G307000, G307100, G308.00, G309.00, G30B.00, G30X.00, G30X000, G30y.00, G30y100, G30y200, G30yz00, G30z.00, G31..00, G310.00, G310.11, G311.00, G311.11, G311.12, G311.13, G311.14, G311000, G311011, G311100, G311200, G311300, G311500, G311z00, G31y.00, G31y000, G31y200, G31y300, G31yz00, G32..00, G32..11, G32..12, G33..00, G330.00, G330000, G330z00, G331.00, G331.11, G332.00, G33z.00, G33z000, G33z100, G33z200, G33z300, G33z400, G33z500, G33z600, G33z700, G33zz00, G34..00, G340.00, G340.11, G340.12, G340000, G340100, G342.00, G343.00, G344.00, G34y.00, G34y000, G34y100, G34yz00, G34z.00, G34z000, G35..00, G350.00, G351.00, G353.00, G35X.00, G360.00, G362.00, G363.00, G364.00, G365.00, G38..00, G380.00, G381.00, G384.00, G38z.00, G3y..00, G3z..00, G574011, G575.00, G575.11, G575.12, G575000, G575100, G575z00, G61..00, G61..11, G61..12, G610.00, G611.00, G612.00, G613.00, G614.00, G615.00, G616.00, G617.00, G618.00, G61X.00, G61X000, G61X100, G61z.00, G63..00, G63..11, G632.00, G63y000, G63y100, G64..12, G64..13, G640.00, G640000, G641.00, G641.11, G641000, G64z.00, G64z.11, G64z.12, G64z000, G64z111, G64z200, G64z300, G64z400, G66..00, G66..11, G66..12, G66..13, G661.00, G662.00, G663.00, G664.00, G665.00, G666.00, G667.00, G668.00, G671.00, G671000, G671z00, G676000, G6W..00, G6X..00, G70..00, G700.00, G73..00, G73..12, G73y.00, G73yz00, G73z.00, G73z000, G73z011, G73zz00, G742z00, G74y300, G76z000, Gyu3.00, Gyu3200, Gyu3300, Gyu3400, Gyu3600, Gyu6200, Gyu6300, Gyu6400, Gyu6F00, Gyu6G00, Gyu7400</td><td align="left" rowspan="1" colspan="1">ICD 10: I20&#x02010;I99, G45</td><td align="left" rowspan="1" colspan="1">ICD 10: I20&#x02010;I99; G45ICD 9 : 4111 &#x02010; 4131 &#x02010; 4130 &#x02010; 4139 &#x02013; 41000 &#x02010; 41001 &#x02010; 41002 &#x02010; 41010 &#x02010; 41011 &#x02010; 41012 &#x02010; 41030 &#x02010; 41031 &#x02013;41032 &#x02010; 41020 &#x02010; 41021 &#x02010; 41022 &#x02010; 41040 &#x02010; 41041 &#x02010; 41042 &#x02010; 41050 &#x02013; 41051 &#x02010; 41052 &#x02010; 41060 &#x02010; 41061 &#x02010;41062 &#x02010; 41080 &#x02010; 41081 &#x02010; 41082 &#x02013; 41090 &#x02010; 41091 &#x02010; 41092 &#x02010; 41070 &#x02010; 41071 &#x02010; 41072 &#x02010; 42979 &#x02010; 41181 &#x02013;4110 &#x02010; 41189 &#x02010; 41400 &#x02010; 41401 &#x02010; 4292 &#x02010; 412 &#x02010; 41410 &#x02010; 41419 &#x02013; 41411 &#x02010; 41412 &#x02010; 4148 &#x02010; 41402 &#x02013; 41403 &#x02010; 41404 &#x02010; 41405 &#x02010; 41406 &#x02013; 41407 &#x02010; 4142 &#x02010; 4143 &#x02010; 4144 &#x02010;4149 &#x02010; 42611 &#x02010; 42612 &#x02010; 42613 &#x02013; 4260 &#x02010; 42610 &#x02010; 42650 &#x02010; 4262 &#x02013; 4263 &#x02010; 4264 &#x02010; 42651 &#x02010; 42652 &#x02010; 42653 &#x02010; 42654 &#x02010; 4266 &#x02013; 4267 &#x02010; 42681 &#x02010; 42682 &#x02010; 42689 &#x02013;4269 &#x02010; 4275 &#x02010; 4270 &#x02010; 4271 &#x02010; 4272 &#x02013; 42731 &#x02010; 42732 &#x02010; 42741 &#x02010; 42742 &#x02013; 42761 &#x02010; 42769 &#x02010; 42760 &#x02010; 42781 &#x02013;42789 &#x02010; 4279 &#x02010; 4281 &#x02010; 42820 &#x02013; 42821 &#x02010; 42822 &#x02010; 42823 &#x02010; 42830 &#x02013; 42831 &#x02010; 42832 &#x02010; 42833 &#x02010; 42840 &#x02013;42841 &#x02010; 42842 &#x02010; 42843 &#x02010; 4280 &#x02013; 4289 &#x02010; 9971 &#x02010; 40201 &#x02010; 40211 &#x02013; 40291 &#x02010; 430 &#x02010; 431 &#x02010; 4321 &#x02010; 4320 &#x02013;4329 &#x02010; 43321 &#x02010; 43311 &#x02010; 43391 &#x02013; 43301 &#x02010; 43401 &#x02010; 43411 &#x02010; 43491 &#x02013; 43331 &#x02010; 43381 &#x02010; 4350 &#x02010; 4351 &#x02013;4353 &#x02010; 4358 &#x02010; 4377 &#x02010; 4352 &#x02013; 4359</td><td align="left" rowspan="1" colspan="1">ICD 10: I20&#x02010;I99, G45</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ischaemic Heart Disease</td><td align="left" rowspan="1" colspan="1">First incident or fatal IHD</td><td align="left" rowspan="1" colspan="1">G3&#x02026;00, G3&#x02026;11, G3&#x02026;12, G3&#x02026;13, G30..00, G30..11, G30..12, G30..13, G30..14, G30..15, G30..16, G30..17, G300.00, G301.00, G301000, G301100, G301z00, G302.00, G303.00, G304.00, G305.00, G306.00, G307.00, G307000, G307100, G308.00, G309.00, G30A.00, G30B.00, G30X.00, G30X000, G30y.00, G30y000, G30y100, G30y200, G30yz00, G30z.00, G31..00, G310.00, G310.11, G311.00, G311.11, G311.12, G311.13, G311.14, G311000,, G311011, G311100, G311200, G311300, G311400, G311500, G311z00, G312.00, G31y.00, G31y000, G31y100, G31y200, G31y300, G31yz00, G32..00, G32..11, G32..12, G33..00, G330.00, G330000, G330z00, G331.00, G331.11, G332.00, G33z.00, G33z000, G33z100, G33z200, G33z300, G33z400,G33z500, G33z600, G33z700, G33zz00, G34..00, G340.00, G340.11, G340.12, G340000, G340100, G342.00, G343.00, G344.00, G34y.00, G34y000, G34y100, G34yz00, G34z.00, G34z000, G35..00, G350.00, G351.00, G353.00, G35X.00, G36..00, G360.00, G361.00, G362.00, G363.00, G364.00, G365.00, G366.00, G38..00, G380.00, G381.00, G384.00, G38z.00, G3y..00, G3z..00</td><td align="left" rowspan="1" colspan="1">ICD 10: I20&#x02010;I25</td><td align="left" rowspan="1" colspan="1">ICD 10: I20&#x02010;I25ICD 9 : 4111 &#x02010; 4131 &#x02010; 4130 &#x02013; 4139 &#x02010; 41000 &#x02010; 41001 &#x02010; 41002 &#x02013; 41010 &#x02010; 41011 &#x02010; 41012 &#x02010; 41030 &#x02013;41031 &#x02010; 41032 &#x02010; 41020 &#x02010; 41021 &#x02013; 41022 &#x02010; 41040 &#x02010; 41041 &#x02010; 41042 &#x02013; 41050 &#x02010; 41051 &#x02010; 41052 &#x02010; 41060 &#x02013;41061 &#x02010; 41062 &#x02010; 41080 &#x02010; 41081 &#x02013; 41082 &#x02010; 41090 &#x02010; 41091 &#x02010; 41092 &#x02013; 41070 &#x02010; 41071 &#x02010; 41072 &#x02010; 42979 &#x02013;41181 &#x02010; 4110 &#x02010; 41189 &#x02010; 41400 &#x02013; 41401 &#x02010; 4292 &#x02010; 412 &#x02010; 41410 &#x02013; 41419 &#x02010; 41411 &#x02010; 41412 &#x02010; 4148 &#x02013; 41402 &#x02010; 41403 &#x02010; 41404 &#x02010; 41405 &#x02013; 41406 &#x02010; 41407 &#x02010; 4142 &#x02010; 4143 &#x02013; 4144 &#x02010; 4149</td><td align="left" rowspan="1" colspan="1">ICD 10: I20&#x02010;I25</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Acute Myocardial Infarction</td><td align="left" rowspan="1" colspan="1">First incident or fatal AMI</td><td align="left" rowspan="1" colspan="1">323..00, 3233.00, 3234.00, 3235.00, 3236.00, 323Z.00, 889A.00, G30..00, G30..11, G30..12, G30..13, G30..14, G30..15, G30..16, G30..17, G300.00, G301.00, G301000, G301100, G301z00, G302.00, G303.00, G304.00, G305.00, G306.00, G307.00, G307000, G307100, G308.00, G309.00, G30A.00, G30B.00, G30X.00, G30X000, G30y.00, G30y000, G30y100, G30y200, G30yz00, G30z.00, G310.11, G31y100, G35..00, G350.00, G351.00, G353.00, G35X.00, G36..00, G360.00, G361.00, G362.00, G363.00, G364.00, G365.00, G366.00, G38..00, G380.00, G381.00, G384.00, G38z.00, G501.00, Gyu3400</td><td align="left" rowspan="1" colspan="1">ICD 10: I21</td><td align="left" rowspan="1" colspan="1">ICD 10: I21ICD 9 : 41000 &#x02010; 41001 &#x02010; 41002 &#x02013; 41010 &#x02010; 41011 &#x02010; 41012 &#x02010; 41030 &#x02013; 41031 &#x02010; 41032 &#x02010; 41020 &#x02010; 41021 &#x02013;41022 &#x02010; 41040 &#x02010; 41041 &#x02010; 41042 &#x02013; 41050 &#x02010; 41051 &#x02010; 41052 &#x02010; 41060 &#x02013; 41061 &#x02010; 41062 &#x02010; 41080 &#x02010; 41081 &#x02010;41082 &#x02010; 41090 &#x02010; 41091 &#x02010; 41092 &#x02013; 41070 &#x02010; 41071 &#x02013; 41072</td><td align="left" rowspan="1" colspan="1">ICD 10: I21</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Arrhythmia</td><td align="left" rowspan="1" colspan="1">First incident or fatal arrhythmia</td><td align="left" rowspan="1" colspan="1">14AN.00, 14AR.00, 212R.00, 327..00, 3272, 3273, 328..00, 3282, 328Z.00, 662S.00, 6A9..00, 7936A00, 8CMW200, 8HTy.00, 9Os..00, 9Os0.00, 9Os1.00, 9Os2.00, 9Os3.00, 9Os4.00, 9hF..00, 9hF1.00, G559.00, G55A.11, G56..00, G56..11, G567400, G56y.00, G56y000, G56zz00, G57..00, G57..11, G570.00, G570000, G570100, G570200, G570300, G570z00, G571.00, G571.11, G572.00, G572000, G572z00, G573.00, G573000, G573100, G573200, G573300, G573400, G573500, G573600, G573z00, G574.00, G574100, G574z00, G576300, G576400, G576500, G57y.00, G57y600, G57y900, G57yA00, G57yz00, G57z.00, Gyu5a00, I45.6, I47, I47.0, I47.1, I47.2, I47.9, I48, I49, I49.0, I49.1, I49.2, I49.3, I49.4, I49.5, R00.0</td><td align="left" rowspan="1" colspan="1">ICD 10: I44&#x02010; I49</td><td align="left" rowspan="1" colspan="1">ICD 10: I44&#x02010; I49ICD 9 : 42611 &#x02010; 42612 &#x02010; 42613 &#x02013; 4260 &#x02010; 42610 &#x02010; 42650 &#x02010; 4262 &#x02013; 4263 &#x02010; 4264 &#x02010; 42651 &#x02010; 42652 &#x02013; 42653 &#x02010; 42654 &#x02010; 42650 &#x02010; 4266 &#x02013; 4267 &#x02010; 42681 &#x02010; 42682 &#x02010; 42689 &#x02013;4269 &#x02010; 4275 &#x02010; 4270 &#x02010; 4271 &#x02010; 4272 &#x02013; 42731 &#x02010; 42732 &#x02010; 42741 &#x02010; 42742 &#x02013; 42761 &#x02010; 42769 &#x02010; 42760 &#x02010; 42781 &#x02013;42789 &#x02013; 4279</td><td align="left" rowspan="1" colspan="1">ICD 10: I44&#x02010; I49</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Heart Failure</td><td align="left" rowspan="1" colspan="1">First incident or fatal HF</td><td align="left" rowspan="1" colspan="1">1O1..00, 402 C, 4270, 4270C, 4270CC, 4270D, 4270DR, 4270LW, 4270R, 4271, 4271A, 4271H, 428 A, 7824A, 7824AC, 7824FC, 7824FH, G1yz100, G232.00, G234.00, G58..00, G58..11, G580.00, G580.11, G580.12, G580.13, G580.14, G580000, G580100, G580200, G580300, G581.00, G581.11, G581.12, G581.13, G581000, G582.00, G58z.00, G58z.12</td><td align="left" rowspan="1" colspan="1">ICD 10: I50, I97.710, I97.790, I11.0</td><td align="left" rowspan="1" colspan="1">ICD 10: I50, I97.710, I97.790, I11.0ICD 9 :4281 &#x02010; 42820 &#x02010; 42821 &#x02013; 42822 &#x02010; 42823 &#x02010; 42830 &#x02010; 42831 &#x02013; 42832 &#x02010; 42833 &#x02010; 42840 &#x02010; 42841 &#x02013; 42842 &#x02010; 42843 &#x02010; 4280 &#x02010; 4289 &#x02013; 9971 &#x02010; 40201 &#x02010; 40211 &#x02013; 40291</td><td align="left" rowspan="1" colspan="1">ICD 10: I50, I97.710, I97.790, I11.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stroke</td><td align="left" rowspan="1" colspan="1">First incident or fatal stroke</td><td align="left" rowspan="1" colspan="1">4350AT, 4359AT, 4360A, 4360B, 4369A, 4369AL, 4369AR, 4369B, 4369BN, G61..00, G61..11, G61..12, G610.00, G611.00, G612.00, G613.00, G614.00, G615.00, G616.00G618.00, G61X.00, G61X000, G61X100, G61z.00, G63y000, G63y100, G64..00, G64..11, G64..12, G64..13, G640.00, G640000, G641.00, G641.11, G641000, G64z.00, G64z.11, G64z.12, G64z000, G64z100, G64z111, G64z200, G64z300, G64z400, G65..00, G65..11, G65..12, G65..13, G650.00, G650.11, G651.00, G651000, G652.00, G653.00, G654.00, G656.00, G65y.00, G65z.00, G65z000, G65z100, G65zz00, G66..00, G66..11, G66..12, G66..13, G660.00, G661.00, G662.00, G663.00, G664.00, G665.00, G666.00, G667.00, G668.00, G6W..00, G6X..00, Gyu6200, Gyu6300, Gyu6400, Gyu6500, Gyu6600, Gyu6G00, L440.11, L440.12</td><td align="left" rowspan="1" colspan="1">ICD 10: I60&#x02010;64, G45</td><td align="left" rowspan="1" colspan="1">ICD 10: I60&#x02010;64, G45ICD 9 : 430 &#x02010; 431 &#x02010; 4321 &#x02010; 4320 &#x02013; 4329 &#x02010; 43321 &#x02010; 43311 &#x02010; 43391 &#x02013; 43301 &#x02010; 43401 &#x02010; 43411 &#x02010; 43491 &#x02013;43331 &#x02010; 43381 &#x02010; 4350 &#x02010; 4351 &#x02013; 4353 &#x02010; 4358 &#x02010; 4377 &#x02010; 4352 &#x02013; 4359</td><td align="left" rowspan="1" colspan="1">ICD 10: I60&#x02010;64, G45</td></tr><tr><td align="left" colspan="6" rowspan="1">Other variables defined by readcodes or drugcodes in UK and ICD or ATC codes in France, Belgium and the Netherlands</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">Algorithm using readcodes, ATC codes, BNF codes and drugcodes</td><td align="left" rowspan="1" colspan="1"> Panel 1 (Figure <xref rid="fcp12454-fig-0002" ref-type="fig">2</xref>)</td><td align="left" rowspan="1" colspan="1"> Panel 2 (<italic>Figure</italic>
<xref rid="fcp12454-fig-0002" ref-type="fig">2</xref>) + ATC codes :C09AA01 &#x02010; C09AA02 &#x02010; C09AA03 &#x02013; C09AA04 &#x02010; C09AA05 &#x02010; C09AA06 &#x02013; C09AA07 &#x02010; C09AA08 &#x02010; C09AA09 &#x02013;C09AA10 &#x02010; C09AA11 &#x02010; C09AA12 &#x02013; C09AA13 &#x02010; C09AA14 &#x02010; C09AA15 &#x02013; C09AA16 &#x02010; C07AA01 &#x02010; C07AA02 &#x02013;C07AA03 &#x02010; C07AA05 &#x02010; C07AA06 &#x02013; C07AA07 &#x02010; C07AA12 &#x02010; C07AA14 &#x02010; C07AA15 &#x02010; C07AA16 &#x02010; C07AA17 &#x02013;C07AA19 &#x02010; C07AA23 &#x02010; C07AA27 &#x02013; C07AB01 &#x02010; C07AB02 &#x02010; C07AB03 &#x02013; C07AB04 &#x02010; C07AB05 &#x02010; C07AB06 &#x02013;C07AB07 &#x02010; C07AB08 &#x02010; C07AB09 &#x02013; C07AB10 &#x02010; C07AB11 &#x02010; C07AB12 &#x02013; C07AB13 &#x02010; C07AB14 &#x02010; C08CA01 &#x02013;C08DB01 &#x02010; C08CA02 &#x02010; C08CA03 &#x02013; C08CA04 &#x02010; C08CA05 &#x02010; C08CA55 &#x02013; C08DA01 &#x02010; C08DA51 &#x02010; C03AA01 &#x02013;C03AA02 &#x02010; C03AA03 &#x02010; C03AA04 &#x02013; C03AA05 &#x02010; C03AA06 &#x02010; C03AA07 &#x02013; C03AA08 &#x02010; C03AA09 &#x02010; C03AA13 &#x02013;C03AB01 &#x02010; C03AB02 &#x02010; C03AB03 &#x02013; C03AB04 &#x02010; C03AB05 &#x02010; C03AB06 &#x02013; C03AB07 &#x02010; C03AB08 &#x02010; C03AB09 &#x02010;C07BA02 &#x02010; C07BA05 &#x02010; C07BA06 &#x02013; C07BA07 &#x02010; C07BA12 &#x02010; C07BA68 &#x02013; C07BB02 &#x02010; C07BB03 &#x02010; C07BB04 &#x02013;C07BB06 &#x02010; C07BB07 &#x02010; C07BB12 &#x02013; C07BB52 &#x02010; C09CA09 &#x02010; C09CA06 &#x02013; C09DB07 &#x02010; C09DA06 &#x02010; C09CA02 &#x02013;C09DA02 &#x02010; C09CA04 &#x02010; C09DB05 &#x02013; C09DA04 &#x02010; C09CA01 &#x02010; C09DB06 &#x02013; C09DA01 &#x02010; C09CA08 &#x02010; C09DB02 &#x02013;C09DA08 &#x02010; C09DX03 &#x02010; C09CA07 &#x02013; C09DB04 &#x02010; C09DA07 &#x02010; C09CA03 &#x02013; C09DX02 &#x02010; C09DB01 &#x02010; C09DA03 &#x02013;C09DB08 &#x02010; C09DX04 &#x02010; C09DX01 &#x02013; C02AA01 &#x02010; C02AA02 &#x02010; C02AA03 &#x02013; C02AA04 &#x02010; C02AA05 &#x02010; C02AA06 &#x02013;C02AA07 &#x02010; C02AA52 &#x02010; C02AA53 &#x02010; C02AA57 &#x02010; C02AB01 &#x02010; C02AB02 &#x02013; C02AC01 &#x02010; C02AC02 &#x02010; C02AC04 &#x02013;C02AC05 &#x02010; C02AC06 &#x02010; C02BA01 &#x02013; C02BB01 &#x02010; C02CA01 &#x02010; C02CA02 &#x02013; C02CA03 &#x02010; C02CA04 &#x02010; C02CA06 &#x02013;C02CC01 &#x02010; C02CC02 &#x02010; C02CC03 &#x02013; C02CC04 &#x02010; C02CC05 &#x02010; C02CC06 &#x02013; C02CC07 &#x02010; C02DG01 &#x02010; C02DA01 &#x02013;C02DB01 &#x02010; C02DB02 &#x02010; C02DB03 &#x02013; C02DB04 &#x02010; C02DC01 &#x02010; C02DD01 &#x02013; C02KA01 &#x02010; C02KB01 &#x02010; C02KC01 &#x02013;C02KD01 &#x02010; C02KX01 &#x02010; C02KX02 &#x02013; C02KX03 &#x02010; C02KX04 &#x02010; C02KX05 &#x02013; C02LA01 &#x02010; C02LA02 &#x02010; C02LA03 &#x02013;C02LA04 &#x02010; C02LA07 &#x02010; C02LA08 &#x02013; C02LA09 &#x02010; C02LA50 &#x02010; C02LA51 &#x02010; C02LA52 &#x02010; C02LA71 &#x02010; C02LB01 &#x02013;C02LC01 &#x02010; C02LC05 &#x02010; C02LC51 &#x02013; C02LE01 &#x02010; C02LF01 &#x02010; C02LG01 &#x02013; C02LG02 &#x02010; C02LG03 &#x02010; C02LG51 &#x02013;C02LG73 &#x02010; C02LK01 &#x02010; C02LL01 &#x02013; C02LX01 &#x02010; C02BC &#x02010; C02LN &#x02010; C02N</td><td align="left" rowspan="1" colspan="1"> Panel 1 (<italic>Figure</italic>
<xref rid="fcp12454-fig-0002" ref-type="fig">2</xref>)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dyslipidaemia</td><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">Algorithm using readcodes, ATC codes, BNF codes and drugcodes</td><td align="left" rowspan="1" colspan="1">ICD 10: E78</td><td align="left" rowspan="1" colspan="1">ATC codes : C10AA01 &#x02010; C10AA02 &#x02013; C10AA03 &#x02010; C10AA04 &#x02010; C10AA05 &#x02013; C10AA06 &#x02010; C10AA07 &#x02010; C10AA08 &#x02013; C10AB01 &#x02010; C10AB02 &#x02010; C10AB03 &#x02013; C10AB04 &#x02010; C10AB05 &#x02010; C10AB06 &#x02013; C10AB07 &#x02010; C10AB08 &#x02010; C10AB09 &#x02013; C10AB10 &#x02010; C10AB11 &#x02010; C10AC01 &#x02013; C10AC02 &#x02010; C10AC03 &#x02010; C10AC04 &#x02013; C10AD01 &#x02010; C10AD02 &#x02010; C10AD03 &#x02013; C10AD04 &#x02010; C10AD05 &#x02010; C10AD06 &#x02013; C10AD52 &#x02010; C10AX03 &#x02010; C10AX05 &#x02013; C10AX06 &#x02010; C10AX07 &#x02010; C10AX08 &#x02013; C10AX09 &#x02010; C10AX10 &#x02010; C10AX11 &#x02013; C10AX12 &#x02010; C10AX13 &#x02010; C10AX14</td><td align="left" rowspan="1" colspan="1">ICD 10: E78</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes</td><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">Algorithm using readcodes, ATC codes, BNF codes and drugcodes</td><td align="left" rowspan="1" colspan="1">ICD 10: E10&#x02010;E14</td><td align="left" rowspan="1" colspan="1">ATC codes : A10BA02 &#x02010; A10BD02 &#x02013; A10BD03 &#x02010; A10BD05 &#x02010; A10BD07 &#x02013; A10BD08 &#x02010; A10BD10 &#x02010; A10BD11 &#x02013; A10BD13 &#x02010; A10BD14 &#x02010; A10BD15 &#x02013;A10BD16 &#x02010; A10BD17 &#x02010; A10BD18 &#x02013; A10BD20 &#x02010; A10BB01 &#x02010; A10BB02 &#x02013; A10BB03 &#x02010; A10BB04 &#x02010; A10BB05 &#x02013;A10BB06 &#x02010; A10BB07 &#x02010; A10BB08 &#x02013; A10BB09 &#x02010; A10BB10 &#x02010; A10BB11 &#x02013; A10BB12 &#x02010; A10BB31 &#x02010; A10AB</td><td align="left" rowspan="1" colspan="1">ICD 10: E10&#x02010;E14</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior PCa Treatment</td><td align="left" rowspan="1" colspan="1">Radical prostatectomy before GnRH initiation</td><td align="left" rowspan="1" colspan="1">Readcodes: 7B20000, 7B20200, 7B36.00, 7B36.11, 7B36000, 7B36100, 7B36111, 7B36200, 7B36300, 7B36400, 7B36411, 7B36500, 7B36600, 7B36700, 7B36y00, 7B36z00, 7B36z11, 7B37.00, 7B37000, 7B37200, 7B37y00, 7B37z00, 7B3E.00, 7B3Ez00</td><td align="left" rowspan="1" colspan="1">ICD 10: M6180, M6182, M34.1, M61.2, M61.3, M61.4</td><td align="left" rowspan="1" colspan="1">Nomenclature codes (from health insurance companies : <ext-link ext-link-type="uri" xlink:href="http://ondpanon.riziv.fgov.be/nomen/fr/search">http://ondpanon.riziv.fgov.be/nomen/fr/search</ext-link>) :261796 &#x02013; 261800694610 &#x02010; 694621154851 &#x02010; 154862777114 &#x02010; 777125</td><td align="left" rowspan="1" colspan="1">ICD 10: M6180, M6182, M34.1, M61.2, M61.3, M61.4</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Prior PCa Treatment</td><td align="left" rowspan="1" colspan="1">Radiotherapy</td><td align="left" rowspan="1" colspan="1">5149, 5151., 59&#x02026;00, 597..00, 5971.00, 597Z.00, 59Z..00, 5A&#x02026;11, 5A1..00, 5A16.00, 5A16.11, 5A16.12, 5A17.00, 5A1Z.00, 5A2..00, 5A27.00, 5A28.00, 5A2Z.00, 5A3..00, 5A33.00, 5A3Z.00, 5A4..00, 5A59.00, 5A65.00, 5A8Z.00, 7M37100, XalpH</td><td align="left" rowspan="1" colspan="1">ICD 10: M70.6, M71.2, Z42.2, Z42.2</td><td align="left" rowspan="1" colspan="1">Nomenclature codes (from health insurance companies : <ext-link ext-link-type="uri" xlink:href="http://ondpanon.riziv.fgov.be/nomen/fr/search">http://ondpanon.riziv.fgov.be/nomen/fr/search</ext-link>):444113 &#x02010; 444124444135 &#x02010; 444146444150 &#x02010; 444161444172 &#x02010; 444183444216 &#x02010; 444220444253 &#x02010; 444264444290 &#x02010; 444301444312 &#x02010; 444323</td><td align="left" rowspan="1" colspan="1">ICD 10: M70.6, M71.2, Z42.2, Z42.2</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Smoking Status</td><td align="left" rowspan="1" colspan="1">Current smokers</td><td align="left" rowspan="1" colspan="1">Readcodes: 137%, 8CAL%, 8H%, 8IAj.00, 9NS0200, 9ko%</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Smoking Status</td><td align="left" rowspan="1" colspan="1">Non&#x02010;smokers</td><td align="left" rowspan="1" colspan="1">Readcodes: 1371%, 9kn%</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Smoking Status</td><td align="left" rowspan="1" colspan="1">Smokers</td><td align="left" rowspan="1" colspan="1">Readcodes: 1377, 1378, 1379, 137(A,B,F,K,N,O,S,Tj), 1371.00, 9 km%</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ethnicity</td><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="left" rowspan="1" colspan="1">Readcodes: 9S1%, 9SA9%, 9SI%, 9i1%, 9i2%</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ethnicity</td><td align="left" rowspan="1" colspan="1">Black</td><td align="left" rowspan="1" colspan="1">Readcodes: 9S2%, 9S3%, 9S4%, 9iB%, 9iC%, 9iC%, 9iD%</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ethnicity</td><td align="left" rowspan="1" colspan="1">Asian</td><td align="left" rowspan="1" colspan="1">Readcodes: 9S6%,9S7%,9S8%,9SA8%,9SH%,9i8%,9i9%,9iA%</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Ethnicity</td><td align="left" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">Readcodes: 9S5%, 9S9%,9SA2%,9SA4%,9SAA%, 9SB%,9SJ%,9i3%&#x02010;9i6%,9iA3%,9iA7%,9iE%,9iF%</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI</td><td align="left" rowspan="1" colspan="1">underweight at &#x02264; 18.5</td><td align="left" rowspan="1" colspan="1">Readcodes: 22K3.00, 22K6.00, EMISNQBO29</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI</td><td align="left" rowspan="1" colspan="1">normal at 18.6&#x02013;24</td><td align="left" rowspan="1" colspan="1">Readcodes: 22K1.00, 22K8.00, JHCBO5</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI</td><td align="left" rowspan="1" colspan="1">overweight at 25&#x02013;30</td><td align="left" rowspan="1" colspan="1">Readcodes: 22K2.00, 22K4.00</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI</td><td align="left" rowspan="1" colspan="1">obese at &#x02265; 30</td><td align="left" rowspan="1" colspan="1">Readcodes: 22KC.00, 22KD.00, 22KE.00, 22K7.00, 22K5.00</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Socio&#x02010;economic Status</td><td align="left" rowspan="1" colspan="1">Lowest</td><td align="left" rowspan="1" colspan="1">1 &#x02010; least deprived</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Socio&#x02010;economic Status</td><td align="left" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Socio&#x02010;economic Status</td><td align="left" rowspan="1" colspan="1">Middle</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Socio&#x02010;economic Status</td><td align="left" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Socio&#x02010;economic Status</td><td align="left" rowspan="1" colspan="1">Highest</td><td align="left" rowspan="1" colspan="1">5 &#x02010; most deprived</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Socio&#x02010;economic Status</td><td align="left" rowspan="1" colspan="1">French &#x02018;poor income&#x02019;</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Civil Status</td><td align="left" rowspan="1" colspan="1">Single</td><td align="left" rowspan="1" colspan="1">Single (01), widowed (03), divorced (04), separated(05)</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Civil Status</td><td align="left" rowspan="1" colspan="1">Married</td><td align="left" rowspan="1" colspan="1">Engaged (07), co&#x02010;habiting (08), remarried (09), stable relationship (10), civil partnership (11)</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr></tbody></table><table-wrap-foot id="fcp12454-ntgp-0003"><fn id="fcp12454-note-0003"><label>a</label><p>Further information on nomenclature in Belgium can be found on the RIZIV/INAMI <xref rid="fcp12454-bib-0050" ref-type="ref">50</xref>.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>An algorithm of ICD and ATC codes (<italic>Figure</italic>
<xref rid="fcp12454-fig-0002" ref-type="fig">2</xref>) in Belgium, the Netherlands and France was used to identify men with hypertension as using ICD codes alone resulted in a very low number of hypertensive men in an aged population.</p></sec><sec id="fcp12454-sec-0033"><title>Discussion</title><p>This is the first study to combine real&#x02010;world data from five European countries to compare risk of CVD following GnRH agonists and GnRH antagonists in men with PCa. The ROBINS&#x02010;I tool allowed detailed investigation of our real&#x02010;world study design with an emulated RCT in an attempt to avoid misclassification and unmeasured confounding biases. Extraction of baseline and clinical characteristics defined variables that were to be included in country&#x02010;specific analytical models. Homogenous variables in the five countries were then used in the meta&#x02010;analytical models.</p><p>Real&#x02010;world data or population&#x02010;based observational studies have enabled large&#x02010;scale studies that allow linkages between databases, such as cancer registries, hospital records and epidemiological databases <xref rid="fcp12454-bib-0039" ref-type="ref">39</xref>. According to Booth and Tannock, the way forward in research is to apply RCTs and real&#x02010;world data in a complementary manner. Whereas RCTs provide information on how to improve efficacy and quality of life of cancer patients (because they collect lifestyle factors along with other measurements), real&#x02010;world data provide evidence of improvement in outcome (including safety) at the level of the general population <xref rid="fcp12454-bib-0039" ref-type="ref">39</xref>. Therefore, the ROBINS&#x02010;I tool helped generate a pragmatic approach to our study design to mimic a target trial. It specifically allowed a detailed investigation of trial characteristics, types of biases involved and challenges encountered when using different databases. The ROBINS&#x02010;I tool highlighted some evident and unavoidable biases associated with observational data such as uneven randomization distribution and unmeasured confounding. Although unmeasured confounding is often unavoidable in real&#x02010;world data, VanderWeele (2017) suggests a &#x02018;straightforward&#x02019; E&#x02010;value calculation to quantify the minimum strength of association that an unmeasured confounder would need to have with treatment and outcome in order to explain the treatment&#x02010;outcome association <xref rid="fcp12454-bib-0040" ref-type="ref">40</xref>. For example, higher E&#x02010;values suggest stronger unmeasured confounder associations to explain the estimated effect.</p><p>ROBINS&#x02010;I tool further highlighted indication bias also known as channeling bias in pharmacoepidemiology. Qayyim Said in Yang and West&#x02010;Strum (2010) describes channeling bias as one of the most common type of bias found in pharmacoepidemiology studies. Channeling bias arises when the physician treating patients for a particular disease prescribes certain drugs based on patient characteristics such as severity of disease, age or gender <xref rid="fcp12454-bib-0041" ref-type="ref">41</xref>. We accounted for channeling bias by conducting a stratified meta&#x02010;analysis by HCVDi. Stratification by HCVDi allowed for estimating hazard ratios across two strata: those who had a history of CVD and those who had no history of CVD.</p><p>The use of different codes in the five databases proved difficult to fully homogenize variable definitions. While readcodes and drugcodes were used to identify study variables in the UK, ICD and ATC codes were used in Scotland, Belgium, the Netherlands and France. Moreover, due to missing observations in socio&#x02010;demographic data in the UK, further analyses of lifestyle factors were not possible.</p><p>An algorithm combining ICD and ATC codes (<italic>Figure</italic>
<xref rid="fcp12454-fig-0002" ref-type="fig">2</xref>
<italic>)</italic> in Belgium, the Netherlands and France was used to extract hypertensive men as using ICD codes alone resulted in a very low number of hypertensive men in an aged population. We attempted to avoid classification biases in the five databases by ensuring that data availability, study variable definitions and cohort definitions were as uniform as possible (<italic>Table</italic>
<xref rid="fcp12454-tbl-0003" ref-type="table">3</xref>). As information on compliance to treatment was not available in our databases, this information bias will have to be accounted for when interpreting the results of stage 1 and stage 2 analyses.</p><p>The representativeness of the European PCa population by incorporating five different databases across Europe adds strong value to this study. THIN is a primary healthcare database which represents approximately 6.2% of the UK population <xref rid="fcp12454-bib-0039" ref-type="ref">39</xref>. Whereas THIN is a primary healthcare database, data in the other four databases were of other origins. NHS Scotland provides nationwide medical record linkages between cancer registry, hospital inpatient and outpatient admission, dispensed medications and death certificates <xref rid="fcp12454-bib-0030" ref-type="ref">30</xref>. BCR derives information from standard cancer registration, health insurance companies, hospital discharge data and cause of death data <xref rid="fcp12454-bib-0031" ref-type="ref">31</xref>. The PHARMO Database Network obtains data from both primary and secondary healthcare settings which meant that both cancer registration and follow&#x02010;up visits were reliably available for a patient <xref rid="fcp12454-bib-0035" ref-type="ref">35</xref>. The SNIIRAM database combines a claims database (derived from insurance funds) with hospital&#x02010;derived data to form a large database representative of the French population <xref rid="fcp12454-bib-0036" ref-type="ref">36</xref>. The use of primary healthcare, secondary healthcare and claims databases thus ensured the inclusion of rare, adverse events that may not have been identified in a RCT and adds additional strength to the study.</p><p>We used a two&#x02010;stage approach for the study by investigating heterogeneity in country&#x02010;specific analysis. The country&#x02010;specific analysis was used to describe prescription patterns and the PCa population in the five countries. Stage 2 meta&#x02010;analysis assessed the risk of outcome due to the two exposures investigated. As there was no possibility of combining data at the individual level (due to legal and ethical restrictions), using pooled log&#x02010;transformed hazard ratios of CVD outcomes were the only way to combine the data. In addition to creating a homogenous study protocol, we attempted to further account for heterogeneity using stratified and sensitivity analyses, as described in the methods section.</p><p>The effect of other treatment modalities in addition to GnRH agonists or antagonists needs to be considered when assessing the risk of CVD. This was not considered in detail for this study because full chemotherapy and radiotherapy profiles were not available for all countries. Chemotherapy and radiotherapy are treatment modalities given in a hospital setting, and our data source was limited in this aspect. As a result, we were not able to consider other combination treatment modalities that may have affected CVD outcome. Moreover, data on follow&#x02010;up treatment modalities affecting CVD outcome were missing and were therefore a limitation to the study.</p><p>A further limitation to the study was that CVD history was only considered 12 months prior to GnRH initiation. Although Belgium received information on CVD history for a maximum of 12 months prior to PCa diagnosis, the first GnRH prescription was given immediately or a maximum of four months after PCa diagnosis (90%). In France, access to CVD history was only available during the study period (2010&#x02013;2013) and accurate information on PCa diagnosis date was not available. As CVD history was not consistently available for more than 12 months across the countries, we defined CVD history to be 12 months prior to first GnRH prescription. Therefore, all men included in the study had a minimum of 12 months of CVD history. In order to keep study definitions homogenous across the five countries, we assessed history of CVD using the variable HCVDi.</p><p>The variations in prescription patterns of GnRH antagonists in the five included countries may have influenced the delivery of GnRH antagonists to a specific class of PCa men who were predisposed by factors such as comorbidities and physician preferences. For instance, a physician may have prescribed GnRH antagonists to an individual with a history of CVD based on previous evidence <xref rid="fcp12454-bib-0042" ref-type="ref">42</xref>. This means that GnRH antagonists may have been channeled to this class of PCa men (channeling bias discussed in <italic>Table</italic>
<xref rid="fcp12454-tbl-0001" ref-type="table">1</xref>). Channeling may also explain the different proportions of PCa men on GnRH antagonists across the five countries. A lower number of men on GnRH antagonists was observed in the UK compared to the other four countries, owing to specific guidelines (CG175) <xref rid="fcp12454-bib-0043" ref-type="ref">43</xref>, <xref rid="fcp12454-bib-0044" ref-type="ref">44</xref> only allowing the use of GnRH antagonists in certain PCa men. Although these specific guidelines determined the prescription of GnRH antagonists to advanced hormone&#x02010;dependent PCa men during the study period, current UK National Institute of Clinical Excellence (NICE) guidelines suggest that GnRH antagonists should be prescribed to advanced staged PCa men with a spinal metastasis (NICE TA404) <xref rid="fcp12454-bib-0045" ref-type="ref">45</xref>.</p><p>In Belgium, GnRH antagonists were specified for advanced stage hormone&#x02010;dependent PCa; however, no specifications were made concerning the exact definition of advanced stage, which left room for interpretation by the physician <xref rid="fcp12454-bib-0046" ref-type="ref">46</xref>. In France, although set regulations defined classes of patients for whom GnRH antagonists were prescribed, the decisions were steered mostly by the physicians who may have included PCa men with all T&#x02010;stages with nodal involvement and metastatic disease <xref rid="fcp12454-bib-0047" ref-type="ref">47</xref>. In the Netherlands, the need for rapid testosterone decline was achieved by using GnRH antagonists, with switch to a GnRH agonist after a few months <xref rid="fcp12454-bib-0048" ref-type="ref">48</xref>. Potential differences in prescription and delivery of GnRH antagonists between UK, Scotland, Belgium, the Netherlands and France may thus explain the data heterogeneity between the countries.</p></sec><sec id="fcp12454-sec-0034"><title>Conclusion</title><p>When considering the potential heterogeneity introduced by the variation in the means of recording real&#x02010;world data, pooling data from five different databases were found to be a challenge. However, for the first time we were able to use databases from the UK, Scotland, Belgium, the Netherlands and France to include a heterogeneous PCa population (in contrast to the selected PCa population in RCTs) across Europe to provide results that are more applicable to the general PCa population. The results from this study will help us understand the variations in risk of long&#x02010;term CVD outcomes following GnRH agonists and GnRH antagonists in men with PCa.</p></sec></body><back><ack id="fcp12454-sec-0035"><title>Acknowledgements</title><p>This work was supported by an independent research grant from Ferring Pharmaceuticals. The funder had no influence on the study design, analyses or interpretation of the results. The authors would also like to thank all the healthcare providers and patients contributing information to the UK THIN database, NHS Scotland database, Belgian Cancer Registry, the PHARMO Database Network and the French SNIIRAM database.</p></ack><ref-list content-type="cited-references" id="fcp12454-bibl-0001"><title>References</title><ref id="fcp12454-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="fcp12454-cit-0001">
<string-name>
<surname>Ferlay</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Steliarova&#x02010;Foucher</surname>
<given-names>E.</given-names>
</string-name>, <string-name>
<surname>Lortet&#x02010;Tieulent</surname>
<given-names>J.</given-names>
</string-name> et al. <article-title>Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012</article-title>. <source xml:lang="en">Eur. J. Cancer</source> (<year>2013</year>) <volume>49</volume>
<fpage>1374</fpage>&#x02013;<lpage>1403</lpage>.<pub-id pub-id-type="pmid">23485231</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="fcp12454-cit-0002">
<string-name>
<surname>Kockelbergh</surname>
<given-names>R.</given-names>
</string-name>, <string-name>
<surname>Hounsome</surname>
<given-names>L.</given-names>
</string-name>
<string-name>
<surname>Mayer</surname>
<given-names>E.</given-names>
</string-name>
<article-title>The epidemiology of urological cancer 2001&#x02013;2013</article-title>. <source xml:lang="en">J. Clin. Urol.</source> (<year>2017</year>) <volume>10</volume>(<issue>1S</issue>) <fpage>3</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="fcp12454-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="fcp12454-cit-0003">
<string-name>
<surname>Perlmutter</surname>
<given-names>M.A.</given-names>
</string-name>, <string-name>
<surname>Lepor</surname>
<given-names>H.</given-names>
</string-name>
<article-title>Androgen deprivation therapy in the treatment of advanced prostate cancer</article-title>. <source xml:lang="en">Rev. Urol.</source> (<year>2007</year>) <volume>9</volume>(<issue>Suppl 1</issue>) <fpage>S3</fpage>&#x02013;<lpage>S8</lpage>.</mixed-citation></ref><ref id="fcp12454-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="fcp12454-cit-0004">
<string-name>
<surname>Khan</surname>
<given-names>M.A.</given-names>
</string-name>, <string-name>
<surname>Partin</surname>
<given-names>A.W.</given-names>
</string-name>
<article-title>Management of high&#x02010;risk populations with locally advanced prostate cancer</article-title>. <source xml:lang="en">Oncologist</source> (<year>2003</year>) <volume>8</volume>
<fpage>259</fpage>&#x02013;<lpage>269</lpage>.<pub-id pub-id-type="pmid">12773748</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="fcp12454-cit-0005">
<string-name>
<surname>Braga&#x02010;Basaria</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Dobs</surname>
<given-names>A.S.</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>D.C.</given-names>
</string-name> et al. <article-title>Metabolic syndrome in men with prostate cancer undergoing long&#x02010;term androgen&#x02010;deprivation therapy</article-title>. <source xml:lang="en">J. Clin. Oncol.</source> (<year>2006</year>) <volume>24</volume>
<fpage>3979</fpage>&#x02013;<lpage>3983</lpage>.<pub-id pub-id-type="pmid">16921050</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="fcp12454-cit-0006">
<string-name>
<surname>Keating</surname>
<given-names>N.L.</given-names>
</string-name>, <string-name>
<surname>O'Malley</surname>
<given-names>A.J.</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>M.R.</given-names>
</string-name>
<article-title>Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer</article-title>. <source xml:lang="en">J. Clin. Oncol.</source> (<year>2006</year>) <volume>24</volume>
<fpage>4448</fpage>&#x02013;<lpage>4456</lpage>.<pub-id pub-id-type="pmid">16983113</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="fcp12454-cit-0007">
<string-name>
<surname>McLeod</surname>
<given-names>D.G.</given-names>
</string-name>, <string-name>
<surname>Iversen</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>See</surname>
<given-names>W.A.</given-names>
</string-name> et al. <article-title>Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer</article-title>. <source xml:lang="en">BJU Int.</source> (<year>2006</year>) <volume>97</volume>
<fpage>247</fpage>&#x02013;<lpage>254</lpage>.<pub-id pub-id-type="pmid">16430622</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0008"><label>8</label><mixed-citation publication-type="book" id="fcp12454-cit-0008">
<string-name>
<surname>Petrylak</surname>
<given-names>P.J.</given-names>
</string-name>, <string-name>
<surname>Moul</surname>
<given-names>J.W.</given-names>
</string-name>
<chapter-title>Androgen Ablation for Prostate Cancer: Mechanisms and Modalities</chapter-title>, in: <person-group person-group-type="editor"><name name-style="western"><surname>Kantoff</surname><given-names>P.W.</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Carroll</surname><given-names>P.R.</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>D'Amico</surname><given-names>A.V.</given-names></name></person-group> (Eds), <source xml:lang="en">Prostate cancer: principles and practice</source>. <publisher-name>Williams &#x00026; Wilkins</publisher-name>, <publisher-loc>Lippincott, Philadelphia</publisher-loc>, <year>2002</year>, pp. <fpage>518</fpage>&#x02013;<lpage>523</lpage>.</mixed-citation></ref><ref id="fcp12454-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="fcp12454-cit-0009">
<string-name>
<surname>Saigal</surname>
<given-names>C.S.</given-names>
</string-name>, <string-name>
<surname>Gore</surname>
<given-names>J.L.</given-names>
</string-name>, <string-name>
<surname>Krupski</surname>
<given-names>T.L.</given-names>
</string-name> et al. <article-title>Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer</article-title>. <source xml:lang="en">Cancer</source> (<year>2007</year>) <volume>110</volume>
<fpage>1493</fpage>&#x02013;<lpage>1500</lpage>.<pub-id pub-id-type="pmid">17657815</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="fcp12454-cit-0010">
<string-name>
<surname>Jones</surname>
<given-names>R.D.</given-names>
</string-name>, <string-name>
<surname>Nettleship</surname>
<given-names>J.E.</given-names>
</string-name>, <string-name>
<surname>Kapoor</surname>
<given-names>D.</given-names>
</string-name> et al. <article-title>Testosterone and atherosclerosis in aging men: purported association and clinical implications</article-title>. <source xml:lang="en">Am. J. Cardiovasc. Drugs</source> (<year>2005</year>) <volume>5</volume>
<fpage>141</fpage>&#x02013;<lpage>154</lpage>.<pub-id pub-id-type="pmid">15901202</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="fcp12454-cit-0011">
<string-name>
<surname>D'Amico</surname>
<given-names>A.V.</given-names>
</string-name>, <string-name>
<surname>Denham</surname>
<given-names>J.W.</given-names>
</string-name>, <string-name>
<surname>Crook</surname>
<given-names>J.</given-names>
</string-name> et al. <article-title>Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions</article-title>. <source xml:lang="en">J. Clin. Oncol.</source> (<year>2007</year>) <volume>25</volume>
<fpage>2420</fpage>&#x02013;<lpage>2425</lpage>.<pub-id pub-id-type="pmid">17557956</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="fcp12454-cit-0012">
<string-name>
<surname>Tsai</surname>
<given-names>H.K.</given-names>
</string-name>, <string-name>
<surname>D'Amico</surname>
<given-names>A.V.</given-names>
</string-name>, <string-name>
<surname>Sadetsky</surname>
<given-names>N.</given-names>
</string-name> et al. <article-title>Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality</article-title>. <source xml:lang="en">J. Natl Cancer Inst.</source> (<year>2007</year>) <volume>99</volume>
<fpage>1516</fpage>&#x02013;<lpage>1524</lpage>.<pub-id pub-id-type="pmid">17925537</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="fcp12454-cit-0013">
<string-name>
<surname>O'Farrell</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Garmo</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Holmberg</surname>
<given-names>L.</given-names>
</string-name> et al. <article-title>Risk and timing of cardiovascular disease after androgen&#x02010;deprivation therapy in men with prostate cancer</article-title>. <source xml:lang="en">J. Clin. Oncol.</source> (<year>2015</year>) <volume>33</volume>
<fpage>1243</fpage>&#x02013;<lpage>1251</lpage>.<pub-id pub-id-type="pmid">25732167</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="fcp12454-cit-0014">
<string-name>
<surname>Van Hemelrijck</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Garmo</surname>
<given-names>H.</given-names>
</string-name>, <string-name>
<surname>Holmberg</surname>
<given-names>L.</given-names>
</string-name> et al. <article-title>Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population&#x02010;Based PCBaSe Sweden</article-title>. <source xml:lang="en">J. Clin. Oncol.</source> (<year>2010</year>) <volume>28</volume>
<fpage>3448</fpage>&#x02013;<lpage>3456</lpage>.<pub-id pub-id-type="pmid">20567006</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="fcp12454-cit-0015">
<string-name>
<surname>Barkin</surname>
<given-names>J.</given-names>
</string-name>
<article-title>Risks, benefits, and approaches to hormonal blockade in prostate cancer. Highlights from the European Association of Urology Meeting, March 20&#x02013;24, 2015, Madrid, Spain</article-title>. <source xml:lang="en">Can. J. Urol.</source> (<year>2015</year>) <volume>22</volume>
<fpage>7847</fpage>&#x02013;<lpage>7852</lpage>.<pub-id pub-id-type="pmid">26068639</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="fcp12454-cit-0016">
<string-name>
<surname>Albertsen</surname>
<given-names>P.C.</given-names>
</string-name>, <string-name>
<surname>Klotz</surname>
<given-names>L.</given-names>
</string-name>, <string-name>
<surname>Tombal</surname>
<given-names>B.</given-names>
</string-name> et al. <article-title>Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist</article-title>. <source xml:lang="en">Eur. Urol.</source> (<year>2014</year>) <volume>65</volume>
<fpage>565</fpage>&#x02013;<lpage>573</lpage>.<pub-id pub-id-type="pmid">24210090</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="fcp12454-cit-0017">
<string-name>
<surname>Hopmans</surname>
<given-names>S.N.</given-names>
</string-name>, <string-name>
<surname>Duivenvoorden</surname>
<given-names>W.C.</given-names>
</string-name>, <string-name>
<surname>Werstuck</surname>
<given-names>G.H.</given-names>
</string-name> et al. <article-title>GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model</article-title>. <source xml:lang="en">Urol. Oncol.</source> (<year>2014</year>) <volume>32</volume>
<fpage>1126</fpage>&#x02013;<lpage>1134</lpage>.<pub-id pub-id-type="pmid">25242517</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="fcp12454-cit-0018">
<string-name>
<surname>Rosario</surname>
<given-names>D.J.</given-names>
</string-name>, <string-name>
<surname>Davey</surname>
<given-names>P.</given-names>
</string-name>, <string-name>
<surname>Green</surname>
<given-names>J.</given-names>
</string-name> et al. <article-title>The role of gonadotrophin&#x02010;releasing hormone antagonists in the treatment of patients with advanced hormone&#x02010;dependent prostate cancer in the UK</article-title>. <source xml:lang="en">World J. Urol.</source> (<year>2016</year>) <volume>34</volume>
<fpage>1601</fpage>&#x02013;<lpage>1609</lpage>.<pub-id pub-id-type="pmid">27097892</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0019"><label>19</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0019">
<collab collab-type="authors">ClinicalTrials.gov</collab>
. <article-title>A trial comparing cardiovascular safety of degarelix versus leuprolide in patients with advanced prostate cancer and cardiovascular disease (PRONOUNCE)</article-title>. (<year>2018</year>) Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT02663908">https://clinicaltrials.gov/ct2/show/study/NCT02663908</ext-link> (Accessed date: 05/04/2018).</mixed-citation></ref><ref id="fcp12454-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="fcp12454-cit-0020">
<string-name>
<surname>Scailteux</surname>
<given-names>L.M.</given-names>
</string-name>, <string-name>
<surname>Vincendeau</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Balusson</surname>
<given-names>F.</given-names>
</string-name> et al. <article-title>Androgen deprivation therapy and cardiovascular risk: no meaningful difference between GnRH antagonist and agonists &#x02010; a nationwide population&#x02010;based cohort study based on 2010&#x02010;2013 French Health Insurance data</article-title>. <source xml:lang="en">Eur. J. Cancer</source> (<year>2017</year>) <volume>77</volume>
<fpage>99</fpage>&#x02013;<lpage>108</lpage>.<pub-id pub-id-type="pmid">28390298</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="fcp12454-cit-0021">
<string-name>
<surname>Miettinen</surname>
<given-names>O.S.</given-names>
</string-name>
<article-title>The need for randomization in the study of intended effects</article-title>. <source xml:lang="en">Stat. Med.</source> (<year>1983</year>) <volume>2</volume>
<fpage>267</fpage>&#x02013;<lpage>271</lpage>.<pub-id pub-id-type="pmid">6648141</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="fcp12454-cit-0022">
<string-name>
<surname>Benson</surname>
<given-names>K.</given-names>
</string-name>, <string-name>
<surname>Hartz</surname>
<given-names>A.J.</given-names>
</string-name>
<article-title>A comparison of observational studies and randomized, controlled trials</article-title>. <source xml:lang="en">N. Engl. J. Med.</source> (<year>2000</year>) <volume>342</volume>
<fpage>1878</fpage>&#x02013;<lpage>1886</lpage>.<pub-id pub-id-type="pmid">10861324</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0023"><label>23</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0023">
<string-name>
<surname>George</surname>
<given-names>G.</given-names>
</string-name>, <string-name>
<surname>Scailteux</surname>
<given-names>L.M.</given-names>
</string-name>, <string-name>
<surname>Garmo</surname>
<given-names>H.</given-names>
</string-name> et al. <article-title>The risk of cardiovascular disease following GnRH agonists versus antagonists: real&#x02010;world evidence from four European countries. Poster presented at: Expert&#x02010;guided Poster Presentation</article-title>. 33rd Annual European Association of Urology Congress, Copenhagen, Denmark, (<year>2018a</year>), pp. <fpage>16</fpage>&#x02013;<lpage>20</lpage>.</mixed-citation></ref><ref id="fcp12454-bib-0024"><label>24</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0024">
<string-name>
<surname>George</surname>
<given-names>G.</given-names>
</string-name>, <string-name>
<surname>Scailteux</surname>
<given-names>L.M.</given-names>
</string-name>, <string-name>
<surname>Garmo</surname>
<given-names>H.</given-names>
</string-name> et al. <article-title>Real&#x02010;world insights into risk of cardiovascular disease following GnRH agonists and antagonists in men with prostate cancer</article-title>. Poster presented at: Poster Reception. Global Cardio&#x02010;Oncology Summit 2018, Florida, United States of America, (<year>2018b</year>) 27th &#x02010; 28th September.</mixed-citation></ref><ref id="fcp12454-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="fcp12454-cit-0025">
<string-name>
<surname>Sterne</surname>
<given-names>J.A.C.</given-names>
</string-name>, <string-name>
<surname>Hern&#x000e1;n</surname>
<given-names>M.A.</given-names>
</string-name>, <string-name>
<surname>Reeves</surname>
<given-names>B.C.</given-names>
</string-name> et al. <article-title>ROBINS&#x02010;I: a tool for assessing risk of bias in non&#x02010;randomised studies of interventions</article-title>. <source xml:lang="en">Br. Med. J.</source> (<year>2016</year>) <volume>355</volume>
<fpage>i4919</fpage>.<pub-id pub-id-type="pmid">27733354</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0026"><label>26</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0026">
<string-name>
<surname>Lodwick</surname>
<given-names>R.K.</given-names>
</string-name>
<article-title>THIN database</article-title>. (<year>2015</year>) Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ucl.ac.uk/pcph/research-groups-themes/thin-pub/database">https://www.ucl.ac.uk/pcph/research-groups-themes/thin-pub/database</ext-link> (Accessed date: 05/04/2018).</mixed-citation></ref><ref id="fcp12454-bib-0027"><label>27</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0027">
<collab collab-type="authors">IMS Health Incorporated</collab>
. <article-title>Data content</article-title>. (<year>2015</year>) Available from: <ext-link ext-link-type="uri" xlink:href="http://csdmruk.cegedim.com/our-data/data-content.shtml">http://csdmruk.cegedim.com/our-data/data-content.shtml</ext-link> (Accessed date: 10/10/2017).</mixed-citation></ref><ref id="fcp12454-bib-0028"><label>28</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0028">
<collab collab-type="authors">Vision Health. <italic>Vision Health</italic></collab>
. (<year>2017</year>) Available from: <ext-link ext-link-type="uri" xlink:href="https://www.visionhealth.co.uk/">https://www.visionhealth.co.uk/</ext-link> (Accessed date: 05/04/2018).</mixed-citation></ref><ref id="fcp12454-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="fcp12454-cit-0029">
<string-name>
<surname>Booth</surname>
<given-names>N.</given-names>
</string-name>
<article-title>What are the read codes?</article-title>
<source xml:lang="en">Health Lib. Rev.</source> (<year>1994</year>) <volume>11</volume>
<fpage>177</fpage>&#x02013;<lpage>182</lpage>.</mixed-citation></ref><ref id="fcp12454-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="fcp12454-cit-0030">
<string-name>
<surname>Alvarez&#x02010;Madrazo</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>McTaggart</surname>
<given-names>S.</given-names>
</string-name>, <string-name>
<surname>Nangle</surname>
<given-names>C.</given-names>
</string-name> et al. <article-title>Data resource profile: the Scottish national prescribing information system (PIS)</article-title>. <source xml:lang="en">Int. J. Epidemiol.</source> (<year>2016</year>) <volume>45</volume>
<fpage>714</fpage>&#x02013;<lpage>715f</lpage>.<pub-id pub-id-type="pmid">27165758</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0031"><label>31</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0031">
<collab collab-type="authors">Belgian Cancer Registry</collab>
. <article-title>Belgian Cancer Registry</article-title>. (2017) Available from: <ext-link ext-link-type="uri" xlink:href="http://www.kankerregister.org/Belgian%20Cancer%20Registry">http://www.kankerregister.org/Belgian%20Cancer%20Registry</ext-link> (Accessed date: 05/04/2018).</mixed-citation></ref><ref id="fcp12454-bib-0032"><label>32</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0032">Belgian Law: <article-title>Deliberation No. 09/071 of 15 September 2009, last amended on 18 February 2014, relating to the communication of personal data by insurers to the Cancer Registry Foundation under Article 45 quinquies of the Royal Decree number 78 of 10 November 1967 concerning the practice of health care professions</article-title>.</mixed-citation></ref><ref id="fcp12454-bib-0033"><label>33</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0033">Belgian Law: <article-title>Deliberation No. 16/021 of 15 March 2016 on the communication of coded personal health data by the technical unit to the Cancer Registry Foundation for the assessment of comorbidity in cancer patients in the context of scientific research projects</article-title>.</mixed-citation></ref><ref id="fcp12454-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="fcp12454-cit-0034">
<string-name>
<surname>Van Herk&#x02010;Sukel</surname>
<given-names>M.P.</given-names>
</string-name>, <string-name>
<surname>Van de Poll&#x02010;Franse</surname>
<given-names>L.V.</given-names>
</string-name>, <string-name>
<surname>Lemmens</surname>
<given-names>V.E.</given-names>
</string-name> et al. <article-title>New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System</article-title>. <source xml:lang="en">Eur. J. Cancer</source> (<year>2010</year>) <volume>46</volume>
<fpage>395</fpage>&#x02013;<lpage>404</lpage>.<pub-id pub-id-type="pmid">19811904</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0035"><label>35</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0035">
<collab collab-type="authors">PHARMO Institute</collab>
. <article-title>PHARMO Database Network</article-title>. (<year>2017</year>) Available from: <ext-link ext-link-type="uri" xlink:href="http://pharmo.nl/what-we-have/pharmo-database-network/">http://pharmo.nl/what-we-have/pharmo-database-network/</ext-link> (Accessed date: 05/04/2018).</mixed-citation></ref><ref id="fcp12454-bib-0036"><label>36</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0036">Ameli. <italic>SNIIRAM</italic> (<year>2016</year>) Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ameli.fr/l-assurance-maladie/statistiques-et-publications/sniiram/finalites-du-sniiram.php">https://www.ameli.fr/l-assurance-maladie/statistiques-et-publications/sniiram/finalites-du-sniiram.php</ext-link> (Accessed date: 05/04/2018).</mixed-citation></ref><ref id="fcp12454-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="fcp12454-cit-0037">
<string-name>
<surname>Bezin</surname>
<given-names>J.</given-names>
</string-name>, <string-name>
<surname>Duong</surname>
<given-names>M.</given-names>
</string-name>, <string-name>
<surname>Lassalle</surname>
<given-names>R.</given-names>
</string-name> et al. <article-title>The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology</article-title>. <source xml:lang="en">Pharmacoepidemiol. Drug Saf.</source> (<year>2017</year>) <volume>26</volume>
<fpage>954</fpage>&#x02013;<lpage>962</lpage>.<pub-id pub-id-type="pmid">28544284</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0038"><label>38</label><mixed-citation publication-type="book" id="fcp12454-cit-0038">
<string-name>
<surname>Mackenbach</surname>
<given-names>J.P.</given-names>
</string-name>
<chapter-title>Health and deprivation</chapter-title> in: <person-group person-group-type="editor"><name name-style="western"><surname>Townsend</surname><given-names>P.</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Phillimore</surname><given-names>P.</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>Beattie</surname><given-names>A.</given-names></name></person-group> (Eds), <source xml:lang="en">Inequality and the North</source>. <publisher-name>Croom Helm Ltd</publisher-name>: <publisher-loc>London</publisher-loc>, <year>1987</year>, pp. <fpage>221</fpage>, ISBN 0&#x02010;7099&#x02010;4352&#x02010;0. Health Policy. (1988) 10(2), 207.</mixed-citation></ref><ref id="fcp12454-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="fcp12454-cit-0039">
<string-name>
<surname>Booth</surname>
<given-names>C.M.</given-names>
</string-name>, <string-name>
<surname>Tannock</surname>
<given-names>I.F.</given-names>
</string-name>
<article-title>Randomised controlled trials and population&#x02010;based observational research: partners in the evolution of medical evidence</article-title>. <source xml:lang="en">Br. J. Cancer</source> (<year>2014</year>) <volume>110</volume>
<fpage>551</fpage>&#x02013;<lpage>555</lpage>.<pub-id pub-id-type="pmid">24495873</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="fcp12454-cit-0040">
<string-name>
<surname>VanderWeele</surname>
<given-names>T.J.</given-names>
</string-name>, <string-name>
<surname>Ding</surname>
<given-names>P.</given-names>
</string-name>
<article-title>Sensitivity analysis in observational research: introducing the E&#x02010;value</article-title>. <source xml:lang="en">Ann. Intern. Med.</source> (<year>2017</year>) <volume>167</volume>
<fpage>268</fpage>&#x02013;<lpage>274</lpage>.<pub-id pub-id-type="pmid">28693043</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0041"><label>41</label><mixed-citation publication-type="book" id="fcp12454-cit-0041">
<string-name>
<surname>Said</surname>
<given-names>Q.</given-names>
</string-name>
<chapter-title>Other methodological issues</chapter-title>, in: <person-group person-group-type="editor"><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name></person-group>, <person-group person-group-type="editor"><name name-style="western"><surname>West&#x02010;Strum</surname><given-names>D.</given-names></name></person-group> (Eds), <source xml:lang="en">Understanding pharmacoepidemiology</source>. <publisher-name>The McGraw&#x02010;Hill Companies</publisher-name>, <publisher-loc>United States of America</publisher-loc>, <year>2010</year>, pp. <fpage>105</fpage>&#x02013;<lpage>120</lpage>.</mixed-citation></ref><ref id="fcp12454-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="fcp12454-cit-0042">
<string-name>
<surname>Clyne</surname>
<given-names>M</given-names>
</string-name>. <article-title>Prostate cancer: tipping the balance in favour of degarelix for ADT</article-title>. <source xml:lang="en">Nat. Rev. Urol.</source> (<year>2014</year>) <volume>11</volume>
<fpage>67</fpage>.<pub-id pub-id-type="pmid">24473414</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0043"><label>43</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0043">
<collab collab-type="authors">National Institute for Health and Care Excellence</collab>
. <italic>Degarelix for treating advanced hormone&#x02010;dependent prostate cancer. Final Scope</italic> (<year>2013</year>) Available from: <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/ta404/documents/prostate-cancer-advanced-hormone-dependent-degarelix-depot-final-scope2">https://www.nice.org.uk/guidance/ta404/documents/prostate-cancer-advanced-hormone-dependent-degarelix-depot-final-scope2</ext-link> (Accessed date: 21/02/2018).</mixed-citation></ref><ref id="fcp12454-bib-0044"><label>44</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0044">
<collab collab-type="authors">National Institute for Health and Care Excellence</collab>
. <article-title>Prostate Cancer: diagnosis and treatment</article-title>. (<year>2014</year>) Available from: <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/cg175/evidence/full-guideline-191710765">https://www.nice.org.uk/guidance/cg175/evidence/full-guideline-191710765</ext-link> (Accessed date: 21/02/2018).</mixed-citation></ref><ref id="fcp12454-bib-0045"><label>45</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0045">
<collab collab-type="authors">National Institute for Health and Care Excellence</collab>
. <article-title>Final Appraisal Determination: Degarelix for treating advanced hormone&#x02010;dependent prostate cancer</article-title>. (2014) Available from: <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/ta404/documents/prostate-cancer-advanced-hormone-dependent-degarelix-depot-fad-document2">https://www.nice.org.uk/guidance/ta404/documents/prostate-cancer-advanced-hormone-dependent-degarelix-depot-fad-document2</ext-link> (Accessed date: 06/04/2018).</mixed-citation></ref><ref id="fcp12454-bib-0046"><label>46</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0046">
<article-title>Royal Decree of 31/12/2001 &#x02013; IV &#x02013; 2360000 &#x02013; Law on various health provisions of December 13, 2006, article 39</article-title>. Moniteur Belge (2006).</mixed-citation></ref><ref id="fcp12454-bib-0047"><label>47</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0047">
<collab collab-type="authors">Haute Autorit&#x000e9; De Sant&#x000e9;</collab>
. <article-title>Transparency committee opinion Firmagon</article-title>. (<year>2009</year>) Available from: <ext-link ext-link-type="uri" xlink:href="https://www.has-sante.fr/portail/upload/docs/application/pdf/2011-02/firmagon_ct_6725.pdf">https://www.has-sante.fr/portail/upload/docs/application/pdf/2011-02/firmagon_ct_6725.pdf</ext-link> (Accessed date: 06/04/2018).</mixed-citation></ref><ref id="fcp12454-bib-0048"><label>48</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0048">
<string-name>
<surname>De Boer</surname>
<given-names>J.E.</given-names>
</string-name>
<article-title>CFH&#x02010;rapport 09/19: degarelix (Firmagon<sup>&#x000ae;</sup>)</article-title>. (<year>2009</year>) Available from: <ext-link ext-link-type="uri" xlink:href="https://www.zorginstituutnederland.nl/binaries/zinl/documenten/rapport/2009/07/27/degarelix-firmagon-bij-hormoonafhan0kelijke-prostaatkanker-in-een-vergevorderd-stadium/Degarelix+(Firmagon)+bij+hormoonafhankelijke+prostaatkanker+in+een+vergevorderd+stadium.pdf">https://www.zorginstituutnederland.nl/binaries/zinl/documenten/rapport/2009/07/27/degarelix-firmagon-bij-hormoonafhan0kelijke-prostaatkanker-in-een-vergevorderd-stadium/Degarelix+(Firmagon)+bij+hormoonafhankelijke+prostaatkanker+in+een+vergevorderd+stadium.pdf</ext-link> (Accessed date: 06/04/2018).</mixed-citation></ref><ref id="fcp12454-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="fcp12454-cit-0049">
<string-name>
<surname>Suissa</surname>
<given-names>S.</given-names>
</string-name>
<article-title>Immeasurable time bias in observational studies of drug effects on mortality</article-title>. <source xml:lang="en">Am. J. Epidemiol.</source> (<year>2008</year>) <volume>168</volume>
<fpage>329</fpage>&#x02013;<lpage>335</lpage>.<pub-id pub-id-type="pmid">18515793</pub-id></mixed-citation></ref><ref id="fcp12454-bib-0050"><label>50</label><mixed-citation publication-type="miscellaneous" id="fcp12454-cit-0050">
<collab collab-type="authors">INAMI&#x02010;RIZIV</collab>
. <article-title>Nomenclature: research criteria</article-title>. (<year>2018</year>) Available from: <ext-link ext-link-type="uri" xlink:href="http://ondpanon.riziv.fgov.be/nomen/fr/search">http://ondpanon.riziv.fgov.be/nomen/fr/search</ext-link> (Accessed date: 06/04/2018).</mixed-citation></ref></ref-list></back></article>